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xABSTRACT
Kemp, Arika D. M.S.B.M.E., Purdue University, December 2014. Peripheral Ve-
nous Retroperfusion: Implications for Critical Limb Ischemia and Salvage. Major
Professor: Ghassan S. Kassab.
Peripheral arterial disease is caused by plaque buildup in the peripheral arteries.
Standard treatments are available when the blockage is proximal and focal, however
when distal and diﬀuse the same type of the treatment options are not beneﬁcial due
to the diseased locations. Restoration of blood ﬂow and further salvaging of the limb
in these patients can occur in a retrograde manner through the venous system, called
retroperfusion or arteriovenous reversal. Retroperfusion has been explored over the
last century, where early side to side artery to venous connections had issues with
valve competency prohibiting distal ﬂows, edema buildup, and heart failure. However,
more recent clinical studies create a bypass to a foot vein to ensure distal ﬂows, and
though the results have been promising, it requires a lengthy invasive procedure. It
is our belief that the concerns of both retroperfusion approaches can be overcome in
a minimally invasive/catheter based approach in which the catheter is engineered to
a speciﬁc resistance that avoids edema and the perfusion location allows for valves to
be passable and ﬂow to reach distally. In this approach, the pressure ﬂow relations
were characterized in the retroperfused venous system in ex-vivo canine legs to locate
the optimal perfusion location followed by in-vivo validation of canines. Six canines
were acutely injured for 1-3 hours by surgical ligation of the terminal aorta and both
external iliac arteries. Retroperfusion was successfully performed on ﬁve of the dogs
at the venous popliteal bifurcation for approximately one hour, where ﬂow rates at
peak pressures reached near half of forward ﬂow (37±3 vs. 84±27ml/min) and from
which the slope of the P/F curves displayed a retro venous vasculature resistance that
xi
was used to calculate the optimal catheter resistance. To assess diﬀerences in regional
perfusion, microspheres were passed during retroperfusion and compared to baseline
microspheres passed arterially prior to occlusion in which the ratio of retroperfusion
and forward perfusion levels were near the ratio of reversed and forward venous ﬂow
(0.44) throughout the limb. Decreases in critical metabolites during injury trended
towards normal levels post-retroperfusion. By identifying the popliteal bifurication as
a perfusion site to restore blood ﬂow in the entirety of the distal ischemic limb, showing
reversal of injury, and knowing what catheter resistances to target for further chronic
studies, steps towards controlled retroperfusion and thus more eﬃcient treatment
options can be made for severe PAD patients.
11. INTRODUCTION
1.1 Background
1.1.1 Cardiovascular System
The human need for a cardiovascular system is the result of being a multi-dimensional,
multi-cellular organism [1]. Diﬀusion, the movement of ions, gases, or small molecules
down their concentration gradient, and convection, the movement of water and solutes
across a membrane by a transmembrane pressure gradient, are the basic mechanisms
a single cell needs to stay alive. However, when an organism is or becomes more
complex in size and number of cells, molecular concentration will decrease as the
distance increases as deﬁned by Fick’s Law of Diﬀusion [2]. Therefore the mechanism
at which a cell receives and delivers its nutrients and wastes, respectively, requires a
more eﬃcient delivery system.
The cardiovascular system has evolved into a very eﬃcient delivery system due
to the major branching that occurs. Cells can easily obtain their nutrients when
the diﬀusion distance is no longer an issue. The ﬂuid which brings the nutrients
and waste to and from the tissue, requires ﬂow so cells can continue to receive fresh
new nutrients, and wastes can be properly disposed. The movement of blood is
largely due to the pumping action of the heart. As the heart pumps, it creates a
necessary pressure gradient for the blood to circulate throughout the body via the
major branching [3]. The anatomy and physiology of circulation, and the mechanics
of blood ﬂow are further discussed.
21.1.1.1 Anatomy and Physiology
Diﬀerent parts of the cardiovascular system have unique structures, functions, and
properties. The basic components are the heart, vessels, and blood. The heart acts
as a pump to distribute the transport medium, blood, throughout the body through
conduit-like vessels. The circulation of blood is critical for cell survival because it
contains nutrients and oxygen needed for energy production and metabolism [1].
The cardiovascular system can be broken up into two subsystems, the pulmonary
and systemic. Figure 1.1 shows the pulmonary circulation occurring between the
right and left heart; this circulation is necessary for gas exchange to occur. When
the oxygen-poor blood reaches the right side of the heart through either the superior
venae cavae from upper body and brain, or the inferior venae cavae from the lower
body, it is then pumped into left or right lung via the pulmonary artery. The waste
gas, carbon dioxide, that the cells gave oﬀ during circulation is released and further
exhaled whereas oxygen, obtained from inhalation, is picked up by the red blood cells
for redistribution throughout the body. The now oxygen-rich blood returns to the
left side of the heart via the pulmonary veins where it is then further pumped out to
the rest of the body by the systemic circulation.
Once the oxygen-rich blood is pumped out of the left heart it reaches the systemic
circulation where the largest artery, the aorta, branches to the upper body and brain
and then further descends past the heart to reach the lower body. Both the upper
and lower body receive oxygen-rich blood via the same route: beginning at an elastic
artery, followed by branching into muscular arteries and further into smaller arteries
called arterioles, and again to capillaries where the appropriate gas and nutrient
exchange occurs over a large cross sectional area. The now oxygen-poor blood is
received by the venules which collectively pool into veins that eventually reach the
right heart via the venae cavaes. This cycle of circulation repeats continuously where
each component is uniquely structured to its function.
3Fig. 1.1. This ﬁgure shows a basic schematic of the cardiovascular system. [4]
1.1.1.2 Vasculature Components
All blood vessels move blood throughout the body, however each blood vessel
type has unique structures and properties. Most blood vessel types have three dis-
tinct layers: an inner layer called the tunica intima, a middle layer called the tunica
media, and an outer layer called the tunica externa (Figure 1.2). The innermost
layer comprises of an endothelial layer and a basement membrane plus an additional
internal elastic layer in arteries [5]. The medial layer is comprised of mostly smooth
muscle cells and additional elastic layer for arteries [5]. The outermost layer, or the
adventitia, is mainly composed of collagen, elastin, and other interconnective ﬁbers
of the extracellular matrix [5]. Though both arteries and veins contain all three lay-
ers in general, capillaries only have a tunica intima [5].These structural diﬀerences
correspond with their respective function.
4Arteries are mainly in charge of the delivery of blood from the heart whereas veins
are responsible for the return of blood to the heart and capillaries see to the exchange
of nutrients and waste [5].
Because arteries are the ﬁrst vessels in line to receive the high pressure oxygen-rich
blood, they have a unique composition that permits their function. Figure 1.2 shows
a thick medial section. This medial section is mainly comprised of smooth muscle
cells and is responsible for vessel contraction. Vessel constriction occurs particularly
at the arteriole level which allows capillaries to have a controlled input pressure.
Though large vessels constrict as well, due to the increase in cross sectional area from
arterioles, their contribution to ﬂow regulation is greater. The regulation of pressure
at the capillary level is critical for proper exchange to occur even at times of elevated
pressure, due to standing or exercise, or lowered pressure, due to sleeping, of which
the arteriole would contract or dilate, respectively [1].
Fig. 1.2. This ﬁgure shows the structures of an artery, vein, and
capillary blood vessel. [6]
5The vasculature pressure dynamics are shown in Figure 1.3. It is clear that the
major pressure drop occurs in the arteries, but conversely little to no pressure drop oc-
curs across the venous portion of the circulation pathway. Therefore, the assumption
that veins’ function do not pertain to maintenance of pressure would be true, where
Figure 1.2 reveals that veins have a much thinner medial layer. Figure 1.2 also depicts
a valve within the lumen of the vein attached to the endothelial layer. Valves are nec-
essary for veins to return blood back to heart due to the oxygen-poor blood ﬂowing
against gravity. Besides eﬃcient blood return to the heart, veins also take a role in
blood storage, in which nearly 70% of all resting blood volume resides in the venous
system [3], which is why they are occasionally referred to as capacitance vessels [1].
Veins are very compliant which contributes to their distention in increased pressures,
when transmural pressure increases from 0 to 10mmHg the volume is increased by
200% to combat the increase in pressure [1].
Although the movement of blood is important, the original purpose of blood is to
act as a transport medium for cells to obtain nutrients and oxygen and release waste
and carbon dioxide. The site at which this delivery and return is at the capillary
level. Figure 1.2 reveals the structure of a capillary which, as previously mentioned,
only contains the inner most blood vessel layer, the tunica intima. Similiarly, as to
arteries and veins, a capillary’s structure largely corresponds to its function.
After the blood reaches the arterioles, a large branching network forms, and the
blood is dispersed into a capillary bed of large surface area. Due to a capillary’s size
compared to other blood vessels (∼ 1μm) and the circulatory system being a closed
circuit (i.e. ﬂow rate is constant), Equation 1.1 expresses what ultimately occurs at
a capillary. Because the ﬂow rate (Q) is constant and the cross sectional area (A) of
a capillary is very small, the velocity (V ) will dramatically decrease at the capillary
level. Combining all these characteristics, maximum oxygen and nutrient exchange
will take place by cause of the large amount of area and slowed speeds [1]. How
exchange happens is explained into further detail of the microcirculation.
Q = V A, (1.1)
6Fig. 1.3. This ﬁgure shows the pressure dynamics of the vasculature. [1]
1.1.1.3 Microcirculation
The movement of blood in the smallest blood vessels is done by the microcir-
culation. The role of arterioles, as previously mentioned, are to control the input
pressures to a capillaries, because of this crucial function arterioles are also known as
”resistance vessels”. By contracting when exposed to high pressure levels, the cross
sectional area decreases and thus the resistance increases. The Hagen-Poiseuille re-
lationship (Equation 1.2) easily shows how a decrease in cross sectional area results
in a large increase in resistance and thus a larger pressure drop before entering the
capillaries (1.3) [7].
R =
8πμl
(CSA)2
, (1.2)
ΔP = QR, (1.3)
7Although pressure maintenance before entering capillaries is critical for proper ex-
change to take place, various other parameters also factor into eﬃcient exchange. The
net movement of ﬂuid in capillaries, or ”exchange vessels” is governed by Starling’s
Equation.
J = L([Pc − Pi]− σ[πc − πi]), (1.4)
In summary, the net ﬂuid movement (J) is equal to the diﬀerence of ﬂuid ﬁltered
out in the tissue and ﬂuid reabsorbed back in the blood stream. The P and π
terms indicate the hydrostatic pressure and oncotic pressures, respectively, and c
and i, capillaries and interstitial space, respectively. L is the conductivity constant
dependent on the permeability and surface area of the capillary and σ represents the
idealness of protein movement across the membrane (typically 1 for plasma proteins)
[1].
The hydrostatic pressure of the capillaries is equivalent to the inlet pressure of
blood whereas of the interstitial space it is the tissue pressure acting on the capillar-
ies. Here, the usual laws of diﬀusion are overshadowed by the presence of hydrostatic
pressure [8]. Oncotic pressure represents the driving force of ﬂuid due to protein con-
centration. E.g. the force of entering blood pushes ﬂuid out into tissue, however this
results in an increase of protein concentration left in the blood. This higher oncotic
pressure then drives the reabsorbance of ﬂuids at the venule end of the capillary [1].
Figure 1.4 explains how these terms interact as the blood travels through a capillary
from arteriole to venule end. Initially, a net ﬁltration will occur at the arteriole end,
but as the blood reaches the venule end a net absorption occurs. Overall, the initial
ﬁltrate and ﬁnal reabsorbate result in a slightly positive net ﬁltration in a healthy
individual [1].
The apparent redundancy of ﬁltering and reabsorbing is because the contents of
what is being ﬁltered out are the nutrients and oxygen on the arteriole side versus
what is being reabsorbed back in is the waste and carbon dioxide on the venule side
of the capillary bed. Besides collecting the oxygen poor blood from the capillaries,
8Fig. 1.4. This ﬁgure shows the driving forces acting on a capillary. [9]
venules also have some ﬁltering functions themselves. Often, white blood cells escape
from venules to reach the tissue to ﬁght infection [1].
How the blood travels throughout the macro- and microcirculation have been
explained to great detail, but as to what causes the blood to move, is discussed in
the following hemodynamic’s section.
91.1.1.4 Hemodynamics
Flow dependencies can be explained by Equation 1.5 where the nature of blood
ﬂow or hemodynamics is expressed by this simple relationship between ΔP , a pressure
diﬀerence, and R, a resistance of what the blood is ﬂowing through [7].
Q = ΔP/R, (1.5)
Blood circulation requires a pressure diﬀerence to be present, as indicated in
Equation 1.5. The major pressure diﬀerence in the cardiovascular system occurs
in the heart, between the aortic root and the right atrium, this diﬀerence propels
blood throughout the body. When blood leaves the left side of heart, the oxygenated
arterial blood is approximately 100 mmHg (i.e. mean arterial pressure) and when the
blood returns to the right side of the heart, the deoxygenated is approximately at 5
mmHg [7]. This resulting pressure diﬀerence drives blood circulation in multi-cellular,
multi-dimensional organisms.
The pressure diﬀerence that occurs systemically, can also be explored locally. Star-
ling’s Equation showed the importance of a pressure diﬀerence at a capillary level for
ﬁltration. At each location along the capillary there is a balance of pressures taking
place resulting in either ﬁltration or reabsorption, but if the pressures equal there
will be no net movement of ﬂuids i.e. no driving force for ﬂow occur. And in a
broader aspect, the hydrostatic pressures at each end of the capillary need to diﬀer
for blood to actually ﬂow through the capillary and for adequate exchange to occur,
respectively. The former is governed by Equation 1.5 and the latter is governed by
Starling’s Equation 1.4.
Although the cardiovascular system has evolved into a reasonably complex system
for multicellular multidimensional organisms, there are various locations in which the
system can be perturbed and lead to a disease state. Relevant diseases that can take
place are discussed in detail.
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1.1.2 Disease
Although the mechanistic nature of the cardiovascular system is fairly straight-
forward, there are various ways for the system to become disrupted. The pumping
action of the heart can begin to fail due to stress from high pressures or become weak
due to overcompensation of an increased workload [1]. The transportation of blood
can become less streamline due to changes in pressures or areas of narrowed ﬂow [10].
The blood itself can become contaminated leading to adverse eﬀects on the endothe-
lial layer of the vessels and thus decrease its ability to properly nourish the body. [10]
Because the components of the system are interconnected, when one component fails
for any reason it largely aﬀects the other components as well. There are countless
ways for the system to be disrupted, and for this investigation the disease of interest
begins with the blood components itself.
1.1.2.1 Development
Blood is the transport medium of the body, and once it becomes contaminated,
just like the water supply to a house, it can cause corrosion of the pipes and eventually,
if not taken care of, the plumping will fail altogether and water will have no way to
travel. This concept of contaminated water leading to pipe corrosion and disruption of
water supply is analogous to blood and the body. When blood becomes contaminated
it can cause endothelial dysfunction (inner most layer of a vessel) and through a series
of steps lead to reduced blood ﬂow [10]. Each stage of this progression is discussed.
The toxins that contaminate blood and begin to destroy the endothelial layer of
blood vessels can come from diﬀerent origins. From food intake to smoking habits,
someone’s diet and lifestyle can largely attribute to cardiovascular disease. The major
irritants include low density lipoproteins (LDLs), toxins from smoking, and high blood
pressure [11].
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1.1.2.2 Plaque Formation
When the blood has increased levels of these irritants, the blood vessel’s inner
most wall begins to dysfunction [11]. As the endothelial layer starts to break down
due to overexposure of these toxins, it is thought that the LDLs move in between
the inner and medial layer, literally making the blood vessel ‘fatty’. In an attempt
to protect the vessel, macrophages try to uptake the LDLs, but the result is a toxic
macrophage, called a foam cell [11]. LDLs continue move in between the inner and
medial and eventually form a ‘fatty streak’ in the blood vessel. As the fatty layer
continues to attract more fats and lipids, this triggers smooth muscles from the medial
layer to migrate into the fatty streak in an attempt to form a ﬁbrous cap [11]. This
ﬁbrous cap results in an overall smaller cross sectional area and thus reduced blood
ﬂow.
1.1.2.3 Blockages
The ﬁbrous cap that results from plaque buildup can eventually block oﬀ the
artery entirely, form a clot, or a piece may break oﬀ [11]. Whatever the case, the
result is massive reduced ﬂow in the artery past or distal to the plaque site or from the
traveling clot/plaque getting lodged in a smaller artery. This massive ﬂow reduction
will cause the tissue distal to the blockage to become ischemic, short of oxygen and
necessary nutrients, and, if prolonged, necrotic, die.
1.1.2.4 Atherosclerosis
Blockage or partial blockage and hardening of arteries due to plaque buildup is
called atherosclerosis [5]. Atherosclerosis mainly occurs in large and medium sized
arteries and depending on where these arteries are located can be detrimental [5].
When blood ﬂow is largely reduced, ischemic and necrotic tissue are the eventual
result. Locations at which the ﬂow is particularly sensitive include coronary, carotid,
renal, and peripherial arteries [5].
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Reduced ﬂow in these arteries causes the speciﬁc diseases of coronary artery dis-
ease, carotid artery disease, chronic kidney disease, and peripheral arterial disease.
Major blockage in each disease results in a heart attack, stroke, kidney failure, and
ulcers (minor tissue death) or gangrene (major tissue death), respectively cite.
The latter of all diseases that may develop from atherosclerosis, is described in
detail in the following section.
1.1.3 Peripheral Arterial Disease
Peripheral arterial disease, or PAD, is the speciﬁc disease of developed atheroscle-
rosis in the periphery. It aﬀects 8 to 12 million Americans, where American men and
women in the sixties age group have a 5% prevalence, and the prevalence increases to
10% and 20% as the age group moves to the seventies and eighties (Figure 1.5) [12,13].
Fig. 1.5. This ﬁgure shows the statistics of peripheral arterial disease
according to CDC [13].
1.1.3.1 Risk Factors
Those susceptible to PAD is a combination of controllable and uncontrollable risk
factors. Some of these risk factors include smoking, obesity, diabetes mellitus, low
physical activity, high cholesterol, and high blood pressure. As previously mentioned,
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age is also a factor, as well as gender and ethnicity. These risk factors are displayed
in a odds ratio in Figure 1.6 where a male is 1 to 2 times more likely at risk for
PAD [10].
Fig. 1.6. This ﬁgure shows the risks of peripheral arterial disease ( [10]).
Even though there is a list of risk factors for PAD, the development of the disease
is equivalent to the process described for atherosclerosis, but located in the periphery,
particularly the legs.
1.1.3.2 Progression of PAD
Throughout PAD, blood ﬂow is reduced in the periphery more and more due to
continual plaque buildup on the arterial wall. Initially, there is little to no symptoms
of the disease, but as the disease progresses pain during exercise, or claudication, is
experienced. As claudication becomes worse, the walking distance of the standard 6-
minute walking test become very short before claudication sets in and eventually pain
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is experienced even during rest [14,15]. In the most severe stages of PAD, minor tissue
lose can cause sores or skin ulcers due to ischemia and later, if the lack of blood ﬂow
covers large areas, gangrene can set in and result in major tissue loss. The progression
of PAD has been previously classied into Fontaine’s Stages, but more recently has
been broken up into grades and categories by Rutherford (Figure 1.7) [10].
Fig. 1.7. This ﬁgure shows the classiﬁcation of peripheral arterial
disease in the old Fontaine stages and new Rutherford categories [10].
Typical clinical assessments include palpation and auscultation of the foot, an
ankle-brachial index (ABI) in which the ratio of ankle pressure to arm pressure is made
(normal is 1.00-1.39 and abnormal is <0.90), a 6 minute walking test, as previously
mentioned, as well as a treadmill test in which the patients is exercised until the
onset of symptoms [14–16]. If the pain experienced during exercise is subsided during
rest, the patient is considered to have intermittent claudication. However, if the pain
does not subside during rest, the patient is considered have the most severe form of
PAD, critical limb ischemia (CLI) [16]. Various types of atherosclerotic lesions can
contribute throughout PAD and at each of these speciﬁc subdivisions.
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1.1.3.3 Atherosclerotic Lesions
Blockages are most likely to occur in the aortoiliac segment (suprainguinal region)
or the femoral-poplital segment (infrainguinal region), shown in Figure 1.8. The
suprainguinal region is more proximal, more risky to treat, but has the best treatment
outcomes (∼ 90% patency after 5 years). The infrainguinal region is more distal, less
risky to treat, but 5 year patency is ∼ 70% [10].
Fig. 1.8. This ﬁgure shows the various atherosclerotic lesions of pe-
ripheral arterial disease with the ﬁrst row aorto-iliac lesions and the
second row fem-popliteal lesions [10].
As opposed to typical focal and proximal blockages, patients with CLI and diabetes
are more likely to have diﬀuse and distally located lesions [10].
1.1.3.4 Treatment Options
Since the main indicator of PAD is claudication, the one who experiences this
pain must be educated enough to know the origin of their pain. Typically, those who
experience claudication do not recognize that their pain is speciﬁcally muscle pain
caused by the reduced blood ﬂow. This reduction in blood ﬂow limits the amount
of oxygen available for the muscles. Muscles need more oxygen when more work is
being done, i.e. more exercise equals more work. However, due to the older age
group that PAD is present in, they may think that their pain is due to old age and
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their deteriorating joints or because PAD has a large overlap with other diseases such
as diabetes their pain can be mistaken for nerve pain or neuropathy (common in
diabetics) [17].
Because PAD has a silent progression, treatment options are critical for each stage
of the disease, particularly the late stages. Initial treatment options include medica-
tions to treat risk factors (high blood pressure and high cholesterol), improve walk-
ing distance (cilostazol and pentoxifylline), and/or antiplatelet activation (aspirin,
Plavix) [10].
If medication proves to not be enough and the plaque buildup has not yet fully
blocked an arterial segment, minimally invasive procedures such as angioplasty and/or
stent placement is considered. Angioplasty is a common cardiovascular procedure
in which a catheter is inserted to the area of interest and a balloon is inﬂated to
temporarily re-open the narrowed artery. To keep the artery open, the same procedure
takes place, but a stent is also released once the balloon is inﬂated to re-open the
artery longer than angioplasty could itself [10].
Once the plaque buildup has led to a full block in blood ﬂow, bypass surgeries are
considered. The grafts used for bypass are mostly accessory veins from the patient.
Synthetic grafts can be used but the patency statistics are continuously much less and
therefore unfavored [10]. Figure 1.9 shows typical artery to artery bypass surgeries
that take place in focal and proximal lesions.
A couple other later stage treatment options include endoarterectomy, where the
plaque is surgically removed, and catheter directed thrombolysis, where a specialized
catheter is used to scrape and remove the plaque buildup [10]. Although there are
other late stage treatment options, bypass surgeries are considered ’the gold standard’
for PAD.
Like previously mentioned, PAD patients with CLI and diabetes are more likely
to have diﬀuse and distal occlusions rather than focal and proximal. These mentioned
treatment options are only feasible for the latter, leaving the former without a common
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Fig. 1.9. This ﬁgure shows an aortobifemoral bypass and a
femoropopliteal bypass that typically take place in later stage PAD
patients [18].
treatment option. Often times, failed treatments and CLI patients are left with the
only treatment option of amputation [10].
Although PAD patients with diﬀuse and distally location occlusions have no com-
mon treatment option, unique revascularization techniques have been explored, par-
ticularly retroperfusion.
1.1.4 Retroperfusion
The common pathway for blood begins in the lung to left heart to artery to ar-
teriole to capillary to venule to vein to right heart to ﬁnish again in the lung. Once
reduced ﬂow occurs in an artery, less nutritive blood can make it to the microcircu-
lation, leaving the previously supplied tissue now in need of oxygen and nutrients.
In the previously described bypass surgeries the blood is rerouted to travel from an
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artery to the graft to distal patent artery as the process continues. For retroperfusion
the blood ﬂow now has diﬀerent pathways it can take.
For more than a hundred years, attempts have been made to explore a new blood
pathway both clinically and experimentally [19]. Rather than the previously men-
tioned forward route, from artery to vein, exploration of the undiseased reverse route
was considered for revascularization of an ischemic area. Since the venous system
is unaﬀected by even the most severe atherosclerotic diseases, it provides an ideal
conduit for blood ﬂow. Various eﬀorts of arteriovenous reversal were explored, but
the main idea fell in two categories, in-situ venous connection and excised venous
graft. This new blood pathway would began at the most distal satsifactory artery
which is then connected surgically to a nearby vein, or an accessory vein was grafted
to a distal vein, in which the blood now has a few ﬂow options. Ideally the ﬂow
would reach the venule level and then to the capillary in this reverse route, but col-
laterals could form between the newly arterialized veins and native vessels in sort
of a natural grafting process, or the ﬂow could be immediately diverted or shunted
to a native venous collateral and completely bypass the microcirculation [20]. This
shunting eﬀect was explained by Heimbacker in 1950 along with a demonstration of
oxygen uptake in reverse perfusion [21]. Additional proof of reverse route exchange
was done by Zweifach in 1940 when he showed reversed venous blood resulted in
colloidal dye to pass along the entire length of the capillary network [8]. Figure 1.10
depicts the diﬀerences of blood routes in a normal case, an occluded case, standard
bypass treatment, and retroperfusion.
1.1.4.1 History
Experimental investigation of this new revascularization technique has been driven
by the portion of PAD patients that do not beneﬁt from conventional surgical tech-
niques of which primarily target proximal and focal occlusions. Beginning just prior
to the 19th century, retroperfusion was considered greatly in cardiac revasculariza-
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Fig. 1.10. This ﬁgure shows the various routes of blood starting from a
normal route, a occlusion (black block represents an occlusion), stan-
dard bypass treatment, and retroperfusion techniques of grafting to a
distal vein and surgically attaching an in-situ vein and then the vari-
ous routes the blood can take from there. A represents the theoretical
and ideal ﬂow of the blood, B represents the blood ﬁnding a native
venous collateral and shunting back to the heat, and C represents
the collaterizations occuring between the newly arterialized veins and
native arteries.
tion [22] and then in the periphery by 1912 [23]. Early experiments of arteriovenous
manipulation was not the result of retroperfusion entirely, but creation of a ﬁstula
(AVF), in which a surgical connection was made directly at the artery end and the
venous end [24]. This encouraged other investigators to explore arteriovenous reversal
(AVR) a few years after, but went in and out of popularity due to inconsistent results
and failed expectations, theoretically, experimentally, and clinically [23–25].
Due to the success being unpredictable and major critical reviews, AVR was left
unexplored for nearly 40 years [24]. Its revival was in 1949 by Leger in Paris once
heparin became available [24, 26]. Jordan and Johnston also described success with
AVR the same year [19], which led to optimistic clinical trials. However, Szilagyi had
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9 clinical trials that all led to major failure due to valve obstructions preventing the
arterial blood in the retro venous system from reaching the distal limb [19]. Various
innovative attempts for revascularization followed of which all failed. One particular
study in 1959 tried to use similar concepts in a typical bypass by use of an in-situ
venous graft with valve destruction, in which the great saphenous vein (GSV) was
connected to the femoral artery and distal end to a patent artery to allow the GSV
to be left in its natural subcutaneous bed, but major branching and shunting from
the arterialized vein resulted [27]. This shunting eﬀect was overcome by recognition
of the valve locations. Certain valves, valves in perforating veins, are oriented to
drain from superﬁcial to deep and prevent deep ﬂow reﬂux into superﬁcial veins, thus
if ﬂow is in the superﬁcial system it can easily be shunted directly to the deep and
completely bypass the microcirculation [27]. The recognition of valve orientation was
a key component in early AVF and AVR studies.
Despite the issues, the intense collateral formation and high blood ﬂow at arteri-
ovenous sites were enough to encourage investigators to continue exploring arteriove-
nous revascularization techniques. A second AVF was put in the extremity in 1976
by Lavigne, only to observe that an additional AVF resulted in left ventricular strain
and ultimately heart failure, a decrease in ﬂow through the more proximal ﬁstula,
and a decrease in perfusion distal to the ﬁstula, thus displaying the limitations of
arterio-venous ﬁstulaes [28]. Johansen and Bernstein in 1979 [25], showed their suc-
cess with arteriovenous reversal in canines once they had a reliable irreversible injury
in which they could ensure native collaterals were not the result of improved ﬂow.
When a full venous reversal from femoral artery to vein (AVR) was made, the dogs
had nearly immediate life-threatening massive edema. To avoid this, a second group
of dogs had an end to side connection from femoral artery to vein (arteriovenous
anastomosis, AVA) for one week and then a full venous reversal. Their second group
of dogs avoided massive edema but could not conﬁrm retrograde perfusion of the
terminal circulation.
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Fig. 1.11. This ﬁgure shows the revascularization techniques explored
in arteriovenous manipulations, arteriovenous reversal (AVR), arteri-
ovenous ﬁstula (AVF), and arteriovenous anastomosis (AVA) [24].
Gerard led an acute retroperfusion experiment in 1981 that explored the diﬀer-
ences between AVF, AVR, and AVA (arteriovenous anastomosis) shown in Figure
1.11. His results indicated AVR could be successful if the reversal takes place as
distally as possible [24].
Graham and associates ran with AVR in 1983 [29], but looked at the popliteal
level for perfusion to test whether ﬂows here could surpass any native venous valves
and reach more distal than ever. Flows were shown to reach more distal in their
experiments. From microsphere injections, they were able to indicate that distal limb
levels were perfused primarily by the reverse venous ﬂow whereas proximal limb levels
suggested supply by stimulation of intense collateralization. To further investigate
the collaterals formed, the same group later proved through assessment of tissue
oxygenation and absence of tissue necrosis that these new vessels provided nutritive
ﬂow to the ischemic limb [30].
As the Graham group led into the discovery of the mechanism for revasculariza-
tion [31], other investigators explored in situ venous anastomosis less and vein graft
removal more which Lengua in 1975 showed success [32]. With the venous graft now
excised its distal end could anastomose at the foot to ensure ﬂow distally as opposed
to in situ when the perfusion site was more proximal and less distal ﬂow was observed.
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More recent clinical trials of retroperfusion have used bypass for distal venous arte-
rialization [33–36], brought about by Lengua’s long-term outcome report in 1995 [37],
and their results have been promising. The current technique is similar to standard
bypass but the distal connection is made with a foot vein rather than the nearest
patent and undiseased artery; the diﬀerences are depicted in Figure 1.12. The graft
of choice, similar to standard bypass procedures, is the patient’s great/long saphenous
vein [33–36]. In some cases, the graft was harvested in situ like earlier retroperfusion
experiments [36], but in order to avoid venous-venous shunting and valve dampening
for distal ﬂow, the vein was exposed cranially up to proximal anastomosis site with
all tributaries ligated, and all valves stripped out with a valvulotome or other cutting
device [33–36], respectively. Other times, the bypass was made as short as possible so
that the distal portion of the saphenous vein could remain and the valves were either
stripped or the graft was anastomosed in reverse [33, 34]. One group even ligated
the great saphenous vein to prevent any major shunting that in return causes high
cardiac output and thus heart failure [38]. The proximal anastomsis was always be-
tween the most distal satisfactory artery and the proximal end of the vein. The distal
anastomosis was made at to either the dorsal venous arch or the medial malleolus
vein. This distal attachment now allows ﬂow directly to the foot, surpassing issues
with distal ﬂow. The overall limb salvage rates were between 83 and 92% [33–36].
1.1.4.2 Limitations
The limitations of retroperfusion fall into two categories, those that used in-situ
venous reversal and those that used excised venous grafting for ﬂow reversal. The
advantages and disadvantages of each are depicted in Figure 1.13.
1.1.4.2.1. In-situ Retroperfusion
The hopefulness and issues with in-situ retroperfusion initially rose from arteri-
ovenous ﬁstulas when high ﬂow rates and undeniable collaterizations formed at the
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Fig. 1.12. This ﬁgure shows the current retroperfusion surgery com-
pared to standard bypass surgery [10].
surgical connection between the artery and vein which allowed the nearby tissue to
survive. However, distal ﬂows were not met and often amputation was still needed
or if the patients had developed heart failure from the resulting high cardiac output
some died [24]. AVRs then came into focus, but the large arterial pressures now being
directed in the venous system was too much for the thin vessels and massive edema
resulted [25]. Pre-conditioning of the venous system followed as AVAs were used with
or without AVR following to avoid excessive edema, however proximal connections at
the femoral level had the venous valves obstructing the ﬂow before reaching distal por-
tions [24,25]. Distal connection, at the popliteal level led to distal ﬂows in foot [29,30],
but then the focus shifted from the actuality of the technique (did limb salvage take
place) to mysteries of the technique and thus time was then spent on the mechanistic
feature of collaterization rather than further validation of the reversal site [31]. From
our research, the only clinical results from the last AVR technique resulted in upper
extremity salvage [39] and large-area foot skin retrograde avulsion [40], but no limb
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Fig. 1.13. This ﬁgure compares the diﬀerent arterivenous manipula-
tions from in-situ: arteriovenous ﬁstula (AVF), arteriovenous reversal
(AVR), arteriovenous anastomosis (AVA), and AVA+AVR, and ex-
cised venous graft. (Images from [10,24]).
salvage investigation. A clinical shift to distal venous arterialization through use of
venous excision resulted [33].
1.1.4.2.2. Excised Retroperfusion
Investigators understood the issue with venous valves and their prevention of
distal ﬂows, so in order to guarantee the latter, an accessory vein was excised and its
valves were destroyed before a distal connection was made in a foot vein (dorsal arch
or medial marginal) [33–36]. The recent results are undeniably exciting reaching near
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90% success rates of limb salvage [33–36]. Although, the requirements of the success
tip the comfort scale as the procedure is highly invasive and lengthy, and destruction
of valves are needed before reattachment takes places.
It could be assumed that the ideal retroperfusion technique would avoid edema,
avoid valve destruction, avoid an invasive and lengthy surgery all while providing
nutritive ﬂow to all ischemic areas and thus salvaging the ischemic limb.
1.2 Objectives
It is believed that all of the current retroperfusion technique concerns can be
overcome in a minimally invasive/cather-based approach in which the catheter itself
provides a engineered speciﬁed resistance that avoids edema and the perfusion location
allows for valves to be passable and ﬂow to reach distally. Our approach merges the
advantages of both retroperfusion techniques without the repercussions of each of the
techniques.
This study is broken up into a series of phases: a theoretical assessment, an ex-vivo
proof of concept, an in-vivo validation of the ex-vivo results and gathering of data,
and ﬁnal calculations of an ideal catheter. The theoretical assessment breaks up the
study in an engineering approach, which reveals what the unknown parameters are
needed for an ideal catheter. The ex-vivo experiments show where and what ﬂows
are possible in retroperfusion to indicate what perfusion location to look at in-vivo
and what hemodynamics we might expect at that location. The in-vivo experiments
address the hemodynamics of the perfusion location under injury, extent of retrograde
ﬂow distribution, and metabolic results of injury reversal. The hemodynamic data
gathered invivo is then added to the theoretical assessment to calculate the ideal
catheter resistance needed to obtain a perfusion pressure that will not result in edema.
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1.2.1 Hypothesis
We hypothesized that peripheral venous ﬂow reversal can be engineered to a
speciﬁc pressure-ﬂow range through hemodynamic analysis of retroperfused canine
hindlimbs. Evaluation of this hypothesis was pursued through the following objec-
tives.
1.3 Methods
Determine how the catheter resistance relates to the physiological sys-
tem. By examination of the experimental setup as a catheter in series with the venous
vasculature, we could solve for the system variables and manipulate the setup to de-
termine the unknown variables. The unknown variables, venous retro-vasculature and
ideal catheter resistance, were then determined through ex-vivo and in-vivo experi-
ments.
Determine the resistance of the venous retro-vasculature most suitable
for eﬀective retroperfusion. Because previous retroperfusion eﬀorts have had
issues rendering the valves incompetent, we needed to determine if and where ﬂow
reversal was even possible. Once the valves were shown passable in ex-vivo canine
hindlimbs we then circulated ﬂuid to gather pressure and ﬂow rates at various regions
of interest in the lower limb to determine if the retroperfusion hemodynamics were
location dependent. Through capturing location speciﬁc hemodynamics, we could
then determine what location would be most suitable for eﬀective retroperfusion with
the characteristics captured at each location.
Determine the resistance of the venous retro-vasculature and charac-
teristics of retroperfusion in-vivo. Because retroperfusion would only take place
in an ischemia limb, an ischemia model was needed to gather meaningful retrop-
erfusion data. An extracorporeal circuit was then put into place to determine the
active hemodynamics at the retroperfusion site. A pressure-ﬂow curve was needed to
evaluate the experimental venous retro-vasculature resistance (i.e. the slope of the
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curve), the variable needed to calculate an ideal catheter resistance that limits the
perfusion pressure to a healthy range. We further characterized the retroperfusion
by observing the perfusion territory of the reversed ﬂow. We accomplished this by
injecting microspheres in the antegrade arterial route pre-injury and in the reversed
venous route post-injury. From here we could get an idea as to where the reversed
ﬂow was going, if it was perfusing muscle, which muscles it was perfusing, and overall
how the perfusion territories compared. Evaluation of distal ﬂow, critical for success-
ful limb salvage, was examined through microspheres in the distal muscles. We also
investigated the metabolic eﬀects of retroperfusion at the chosen perfusion site, the
popliteal vein bifurcation, through blood gas samples. Evaluation of retroperfusion
post injury was critical for proof of the perfusion site as a successful location for limb
salvage.
Determine the ideal catheter resistance given the hemodynamic data
retrieved in in-vivo experiments. The in-vivo experimental pressure-ﬂow data
provided us with a value for venous retro-vasculture resistance. Through use of Hemo-
dynamic Ohm’s law, we could set our experimental pressure and ﬂows equal to arterial
pressure and ﬂows by assuming the same perfusion pressure. A table of ideal catheter
resistances given an input/arterial pressure, target perfusion pressures, and arterial
ﬂow rates was made for reference for the optimal catheter design of which would be
used in clinical setting.
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2. OBJECTIVES
We hypothesize that peripheral venous ﬂow reversal can be engineered to a speciﬁc
pressure-ﬂow range through hemodynamic analysis of retroperfused canine hindlimbs.
Evaluation of this hypothesis was pursued through the following speciﬁc aims.
2.1 Speciﬁc Aims
2.1.1 Speciﬁc Aim 1
Determine how the catheter resistance relates to the physiological sys-
tem. Before any experiments were done an engineering analysis of the system was
required to determine what parameters could be manipulated to give the desired
output. Because the catheter and the system could be broken down to a series of
equations, we hypothesized that the catheter resistance could be engineered to pro-
vide a target pressure output range that minimizes edema but still high enough to
promote transcapillary exchange.
2.1.2 Speciﬁc Aim 2
Determine the resistance of the venous retro-vasculature most suitable
for eﬀective retroperfusion. Once the unknown parameter was determined the-
oretically, a series of experiments were laid out to determine the resistance of the
venous retro-vasculature.
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2.1.2.1 Speciﬁc Aim 2A
Determine whether ﬂow reversals are possible. Because previous retrop-
erfusion eﬀorts had issues rendering the valves incompetent, we needed to explore if
and where ﬂow reversal was even possible. Because a series of in-situ ﬂow reversals
were shown to be possible [29,30] and not [19], we hypothesized that the valves were
passable but would be location dependent.
2.1.2.2 Speciﬁc Aim 2B
Determine if the retroperfusion hemodynamics is location dependent.
Because the incompentency of valves were assumed to be location dependent we also
assumed the retroperfusion hemodynamic characteristics to be location dependent as
well. This means that the resistance of the venous retro-vasculature was hypothesized
to be diﬀerent depending on the location of perfusion.
2.1.2.3 Speciﬁc Aim 2C
Determine what location would be most suitable for eﬀective retrop-
erfusion. After observing retroperfusion at various locations, one site was decided
as the most promising for eﬀective retroperfusion and would be used for in-vivo anal-
ysis. Because the venous system is very interconnected to allow for ﬂow to travel the
path of least resistance, we hypothesized that very distal locations would succumb
to venous-venous shunting whereas more proximal locations can avoid this mostly by
being out of venous-venous collateral network.
2.1.3 Speciﬁc Aim 3
Determine the resistance of the venous retro-vasculature and charac-
teristics of retroperfusion in-vivo. Once a retroperfusion location was decided
from ex-vivo experiments, the same location was explored in-vivo for further analysis.
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2.1.3.1 Speciﬁc Aim 3A
Determine the active hemodynamics at the retroperfusion site. The
pressure-ﬂow relation was collected in-vivo to determine a more realistic relationship
between pressure and ﬂow. Because the venous system has limited control of ﬂow
regulation we hypothesized the hemodynamic characteristics to be similar to ex-vivo.
2.1.3.2 Speciﬁc Aim 3B
Determine the perfusion territory of venous reversed ﬂow compared to
arterial forward ﬂow. The forward and reversed ﬂow was analyzed to determine
if any of reversed ﬂow reached the ischemic muscle. Because previous studies had
success with retroperfusion at the same perfusion site [29,30], we expected to observe
some of the reversed ﬂow in the ischemic muscles.
2.1.3.3 Speciﬁc Aim 3C
Determine the eﬀects of retroperfusion on an acute hindlimb ischemia
canine model. To validate the potential of the retroperfusion site as a beneﬁcial
location to start reversed ﬂow, we analyzed the metabolic eﬀects of retroperfusion
throughout the experiment. Because previous studies had shown success with retrop-
erfusion at the same perfusion site [29, 30], we expected some change in metabolites
due to retroperfusion.
2.1.4 Speciﬁc Aim 4
Determine the ideal catheter resistance given the hemodynamic data
retrieved in in-vivo experiments. By taking the hemodynamic data collected
in-vivo, we could then back calculate to ﬁnd the ideal catheter resistance that would
result in target output pressures given the work done in Aim 1.
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Ultimately work would be done by theoretically assessing peripheral venous retrop-
erfusion and experimentally collecting the characteristics and evidence of retroperfu-
sion as a potentially engineerable therapeutic option for patients with critical limb
ischemia.
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3. METHODS
3.1 Theoretical Basis
Characterization of the catheter and physiological system was done through a circuit
design using fundamental hemodynamic properties.
Determine how the catheter resistance relates to the physiological sys-
tem.
Mathematically, the catheter was assumed to be in series with the venous vascu-
lature. Because blood ﬂow is characterized similar to electricity we thought of the
setup as circuit, but instead of Ohm’s Law (V = IR) we used Equation 3.1 [1]. From
here, basic laws of hemodynamics were used to further evaluate the retroperfusion
system. The components and parameters of the system are shown in Figure 3.1.
ΔP = QR, (3.1)
The input source (PressureInput) to the system, clinically, would be the arte-
rial pressure (IPCatheter) and ﬂow at the proximal end of the catheter located in-
side the artery, the catheter resistance itself (RCatheter), the catheter output pressure
(OPCatheter) or perfusion pressure (IPV asculature) inside the vein, the venous vascu-
lature resistance (RV asculature), and the pressure once the ﬂow has left the venous
system (OPV asculature).
Fundamental hemodynamic Equation (3.1) was then used to solve for various
parameters.
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Fig. 3.1. This ﬁgure shows the theoretical circuit of the experimental
setup and logic to solving unknown variables.
3.2 Ex-vivo Experiments
Ex-vivo hindlimbs were immediately amputated from a healthy acute canine. The
femoral artery was exposed and a 4F sheath was sutured in place. 10ml of heparin
was mixed into a 1l saline bag. A ﬂushed IV line was added to the cannula and
the drip rate was adjusted to 1 drip/second. Once the heparinized saline ﬁnished
ﬂushing the lower vasculature through the arterial system, the cannula was closed
oﬀ. A radiopaque hydrophillic guidewire was then advanced through the femoral vein
under ﬂuoroscopy.
Once the valves were conﬁrmed to be passable, the passive hemodynamics of three
locations were explored. The guidewire was ﬁrst advanced to the location of interest
and then a ﬂushed catheter replaced the wire. To prevent immediate backﬂow the
tip of the catheter was either ligated or a balloon was inﬂated. The catheter was
attached to an experimental setup of pulsatile, retrograde ﬂow. Various pressure in-
puts and outputs to the catheter and ﬂow rates were recorded to capture the passive
hemodynamics of the system.
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Determine whether ﬂow reversals are possible.
Valve Experimentation. After the lower vasculature was ﬂushed with heparinized
saline, a wet hydrophillic guidewire (Roadrunner; Cook Medical, Bloomington, IN)
was advanced barebacked through the femoral vein under ﬂuoroscopy. To pass the
proximal valves either some moderate forward ﬂow was connected to the arterial
cannula and/or the wire was pulled backed and pushed forward until the valve was
passed. The wire was kept very wet and sometimes the leg was straightened to pass
diﬃcult turns in the venous system.
Determine if the retroperfusion hemodynamics is location dependent.
Locations of Interest. Once the valves were passed, three locations had their
passive hemodynamics captured. The locations explored were referred to as ’distal’,
’midway’, and ’proximal’ located at the venous dorsum pedis, the lateral saphenous
vein bifucation, and the popliteal vein bifurication, respectively. Each of the locations
explored in ex-vivo are shown in Figure 3.2 with respect to the ex-vivo leg with tissue
intact, ﬂuoroscopy, and ex-vivo leg after cut down.
Retroperfusion Preparation. The hydrophilic guidewire was advanced to the distal
location and then a ﬂushed catheter was advanced over the wire. Conﬁrmation of
the location of interest was conﬁrmed under ﬂuoroscopy. Before any retro ﬂow was
added to the system an experimental setup to capture all the circuit parameters of
pressure and ﬂow were put into place.
Experimental Setup. The experimental setup consisted of a ﬂuid transducer, a
pressure wire (ComboWire XT Guide Wire; Volcano Corp, Alpharetta, GA), a ﬂow
probe and ﬂowmeter (Transonic Systems Inc, Ithaca, NY), a data acquisition system
(Biopac, Goleta, CA), and a computer to collect the inlet pressure to the catheter,
the outlet pressure to the catheter, the ﬂow rate into the catheter, the data from
the ﬂuid transducer and the ﬂow meter and the DAQ data, respectively and a ﬂow
pump to supply the system with a pulsatile ﬂow. Figure 3.3 shows where each of the
parameters were detected.
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Fig. 3.2. This ﬁgure shows the locations explored during the ex-vivo
experiments with respect to (A) the ex-vivo leg with tissue intact
(medial view), (B) ﬂuoroscopy (medial view), and (C) ex-vivo leg
after cut down (medial, lateral, and plantar view, respectively), where
distal is the venous dorsum pedis, midway is the lateral saphenous vein
bifurcation, and proximal is the popliteal vein bifurcation.
Parameters. Experimentally, PressureInput was the inlet source of the ﬂow pump,
which pulled from a solution of 6% dextran. The inlet pressure of the catheter
(IPCatheter) was detected from a ﬂushed pressure line hooked up to a calibrated ﬂuid
transducer. A 5mm ﬂow probe then sensed the ﬂow rate through a calibration ma-
terial. The pressure wire was placed in catheter to the location of constant ﬂow and
normalized from the command station then advanced to the tip of catheter to collect
the outlet pressure of the catheter (OPCatheter). Once in place, the port was screwed
closed and either a balloon was inﬂated, or the tip of the catheter was ligated to
prevent immediate back ﬂow. (Figure 3.3 shows a balloon inﬂation port).
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Fig. 3.3. This ﬁgure shows where each of the system parameters are
being detected from the experimental setup.
Retroperfusion Measurements. The ﬂushed tubing from the ﬂow pump was con-
nected to the catheter setup, and once no bubbles were conﬁrmed in the line the
pump was turned on the lowest ﬂow rate and stepped up by increments enough to
capture at least every 10mmHg, with approximately 30-45 seconds at each pressure,
and shut oﬀ once pressures begin to plateau or reach 100 mmHg.
Once done at the distal location, the inﬂation or ligature was removed and either
the pressure wire was kept distal to conﬁrm pressures when perfusing from a higher
location or the entire system was pulled back to the next location.
Analysis. All pressures and ﬂow data were collected in AcqKnowledge. The data
was averaged over a homeostatic segment that consisted of 3-5 waveforms.
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3.3 In-vivo Experiments
Animal Preparation. Following overnight fasting, 6 mongrel dogs with 10 weeks
of venous hypertension were sedated with acepromazine (0.025-0.1 mg/kg) and bu-
torphanol (0.2-0.4 mg/kg) either intramuscular or subcutaneous 30 minutes prior to
ﬁnal induction of isoﬂuorane, quickly intubated, and further anethesized with isoﬂu-
orane (2%) and 100% oxygen. An IV line was introduced in their cephalic vein for
continuous infusion of saline with a drip rate of 20 drips/minute. They were placed
on a circulating hot water pad, and their neck, lower abdomen/iliac, and popliteal
levels were shaved. A pulse oximeter was placed on their tongue, a blood pressure
cuﬀ on their right brachealcephalis, and a thermometer in the back of the throat, for
vital recordings of heart rate/oxygen saturation, blood pressure, and temperature,
respectively.
Both carotid arteries were accessed with a 9F sheath to supply nutritive blood to
the extracorporeal circuit and to have a catheter (Catheter A) at the popliteal artery
to collect the retroperfusion eﬄuent after an angiogram of popliteal arterial system
was performed. One jugular vein was accessed with a 8F sheath to infuse 3000 units
of heparin every 1-2 hours.
Baseline Measurements. Initial baseline velocity measurements were made from
ultrasound doppler PW at the popliteal artery and vein bifurcation. The pulse oxime-
ter was placed between their toes and on their superﬁcial digital ﬂexor to detect spO2.
Central blood samples were taken and an arteriogram of the popliteal network was
perform with a White Lumax Catheter, Catheter A. Microspheres were then injected
at the popliteal artery bifurcation before the injury took place.
Injury Model. An ischemic hind-limb was prepared in the either the left or right
hind-limb of all the animals by arterial ligation at the descending aortic bifurcation,
both external iliac arteries, and the terminal aorta (Figure 3.4). Occlusion was con-
ﬁrmed by contrast injection of Catheter A. After approximately 1 hour of occlusion
and at 2-3 hours of occlusion, blood samples were taken (Cook Medical, Bloomington,
IN).
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Fig. 3.4. This ﬁgure shows where each of the injury ligations are lo-
cated, the system parameters are being detected, and the catheter
locations. Catheter A was left in the arterial system for eﬄuent re-
trieval and Catheter B was the retroperfusion catheter.
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Retroperfusion Preparation. Re-perfusion of the microsphered leg began by can-
nulation of the common iliac vein with a 9F sheath. Under ﬂuoroscopy, a radiopaque
hydrophilic guidewire was advanced to the popliteal vein bifurcation and then another
ﬂushed white lumax catheter, Catheter B, replaced the wire. The tip of the catheter
was ligated and once no back ﬂow was conﬁrmed under ﬂuoroscopy Catheter B was
connected to the extracorporeal circuit and ﬂow was added to the circuit.
Final Measurements. The pressure wire was ﬁrst normalized and put into place,
then the catheter was ﬂushed with blood being pulled from the central carotid artery
line. Microspheres were injected at the popliteal vein birucation from Catheter B.
The circuit was reattached to Catheter B and retroperfusion began. After all the
necessary pressure ﬂow was collected, blood samples were collected and the pump
was shut oﬀ. The animal was sacriﬁced with a saturated bolus of potassium chloride,
and muscle samples were immediately taken from the experimental leg.
Determine the resistance of the venous retro-vasculature and charac-
teristics of retroperfusion in-vivo.
Extracorporeal Circuit. The extracorporeal circuit, similar to the ex-vivo exper-
imental setup, consisted of a ﬂuid transducer, a Volcano Combo wire, a ﬂowmeter,
a data acquisition system (Biopac), and a computer to collect the inlet pressure to
catheter b, the outlet pressure to catheter b, the ﬂow rate into catheter b, the data
from the ﬂuid transducer and the ﬂow meter, and the DAQ data, respectively and a
ﬂow pump to supply the system with a pulsatile ﬂow. Figure 3.5 shows where each
of the parameters are detected.
Parameters. Acutely, PressureInput was the supply source of the ﬂow pump,
which pulled from the central carotid artery line. The inlet pressure of the catheter
(IPCatheter) was detected from a ﬂushed pressure line hooked up to a calibrated ﬂuid
transducer. A 5mm ﬂow probe then sensed the ﬂow rate through a calibration mate-
rial. The pressure wire was placed in catheter b to the location of constant ﬂow and
normalized from the command station then advanced to the tip of catheter to collect
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Fig. 3.5. This ﬁgure shows where each of the system parameters are
being detected from the experimental setup.
the outlet pressure of the catheter (OPCatheter). Once in place, the port was screwed
closed and the tip of the catheter was ligated to prevent immediate back ﬂow.
Retroperfusion. After microsphere ﬂushing, the stop cock was replaced, the line
was ﬁlled with fresh blood, and the circuit was reattached to catheter b as the pump
starting retroperfusing at the lowest ﬂow rate. Approximately 1-3 minutes of perfu-
sion was performed at each ﬂow rate or until steady-state pressures resulted, then the
ﬂow rate was stepped up by increments enough to capture at least every 10 mmHg
and stopped increasing the ﬂow rate once distal pressures (OPCatheter) begin to reach
between 70-80 mmHg. Retroperfusion was performed for approximately one hour per
animal.
Analysis. All pressures and ﬂow data were collected in AcqKnowledge. The data
was averaged over a homeostatic segment that consisted of 3-5 waveforms.
Determine the perfusion territory of venous reversed ﬂow compared to
arterial forward ﬂow.
Baseline. Before the injury-occlusion took place, 15μm blue ﬂuorescent micro-
spheres (FluoSpheres Blood Flow; Life Technologies Corporation, Carlsbad, CA) were
injected at the popliteal artery bifurcation by mixing 1.62 ml of microspheres with
manually mixed in with 15 ml of nutritive blood in a 20 ml syringe by use of a stop-
cock. After mixing at a rate of 1 ml/sec for two-three minutes, 1 ml of microsphere
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mixed blood was injected into catheter a every 10 seconds, with one to two mixes
inbetween each injection. Once all the microspheres were injected the syringes were
ﬂushed with 10-15 ml of saline using the same mixing and injection technique.
Retroperfusion. Catheter b was ﬂushed before microsphere injections. The ar-
terial blood ﬁlled tubing from the ﬂow pump was connected to the catheter setup,
and once no bubbles were conﬁrmed in the line the pump was turned on the lowest
setting for approximately one minute to ﬂush catheter b with nutritive blood. The
pump was turned oﬀ and detached from catheter b and a stopcock was placed at the
inlet port in which 0.62 ml of yellow-green microspheres were mixed with 10 ml of
blood and injected using the same mixing, injecting, and ﬂushing method as baseline
microspheres.
Analysis. Muscle from the experimental leg was immediately excised in 1-3 gram
segments in 15 ml conicals for microsphere analysis after the animals were sacriﬁced.
The muscle digestion, ﬁltration, microsphere digestion, and ﬂuorescence measure-
ments were made according to the Fluorescent Microspheres Resource Center [41]
and to the Molecular Probe’s Product Information of the FluoSpheres [42].
The sample locations and weights were recorded. Locations of interest starting
from closest muscle to the perfusion site is the lateral long digital extensor, to anterior
cranial tibial, to posterior medial head to lateral head, next to lateral midway at
superﬁcial digital ﬂexor, to its distal segment to the deep muscle ﬁbularis brevis, to
top of foot (extensor digitalis brevis) to bottom of foot (interosseous) (Figure 3.7).
Potassium hydroxide (4M) was added to each sample at a volume of approximately
4-5 times the sample’s weight (per gram). The muscle samples were kept in the dark
and at room temperature for two weeks for adequate tissue digestion.
The fat was removed from the top layer of the digested muscle by pipette suc-
tion. The sides of the conical were cleaned with a KimWipe and once all possible
fat deposits were removed the conical was vortexed to homogenize the hydrolysate
containing the digested tissue and microspheres. The digested tissue and microsphere
were then physically separated using a negative pressure ﬁltration system (Figure 3.6).
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The outer shell of the Perkin Elmer Filtration Unit was placed inside an Erlenmeyer
ﬂask. To make a tight seal, 4mm plastic tubing was wrapped around the outershell
and paraﬁlmed to the ﬂask. In Step 1 the sample tube (Poretic polycarbonate 8μm
ﬁlters) was placed inside the outshell and the homogenized hydrolysate was poured
over the ﬁltered sample tube. The conical then had 4M KOH added (half the original
hydrolysate volume), vortexed, and poured over the ﬁlter to collect the remaining
microspheres in the conicals. This process was repeated three times to ensure all
remaining microspheres were collected. In Step 2 the ﬁlter was carefully removed
from the tube (clean forceps were used to dislodge the ﬁlter from the tube from the
underside). In Step 3 the ﬁlter was placed in a clean ﬂuorescent 10mm pathlength
cuvette (3.5ml Glass Cell G214; Fisher Scientiﬁc, Hanover Park, IL). Cellosolve ac-
etate (2 ml) was added to the cuvette, closed with its stopper, and placed in the dark
as the microspheres digested for 1 hour.
After the hour of microsphere digestion, the cuvette had its ﬂuorescence read from
a spectrometer (Spectramax M2e; Molecular Devices, Sunnyvale, CA) by exciting the
dyes at their speciﬁc wavelengths and recording the emission light at their respec-
tive maximum emission wavelengths speciﬁc to Cellosolve acetate (Blue (356,424),
Yellow-Green (495,505)). Every sample was excited and recorded 2-3 times to ensure
consistent ﬂuorescent values. Their ﬂuorescence intensities were made relative to each
other according to the Fluorescent Microspheres Resource Center Standard Curves
and to their injected volumes.
A new ﬁltered sample tube was used for each sample, and the forceps, cuvette,
and stopper were thoroughly cleaned with methanol between each sample.
Determine the eﬀects of retroperfusion on an acute hindlimb ischemia
canine model.
All blood samples were collected in a 3ml heparinized syringe, immediately closed
with a capped 22 gauge needle to maintain in-vivo metabolite levels, and placed on
ice.
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Fig. 3.6. This ﬁgure shows the negative pressure ﬁltration system
used for ﬁltrating the microspheres.
Baseline. Central blood samples were taken from the carotid artery and jugular
vein before microspheres were injected.
Occlusion. After approximately 1 hour of occlusion, blood samples were taken
from the catheter a to collect the occlusion eﬄuent, and from the central arterial and
venous sheaths. Blood samples were again collected at 2-3 hours of occlusion and
placed on ice.
Retroperfusion. After the pressure and ﬂow retroperfusio data was collected, blood
samples were taken from catheter a to collect the occlusion eﬄuent, and from the
central arterial and venous sheaths.
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Analysis. All blood samples were analyzed within 3 hours of collection using a
blood gas analyzer (GEM Premier 3000; Instrumentation Laboratory Company, Bed-
ford, MA) and a CO-oximeter (682) system (Instrumentation Laboratory Company).
3.4 Theoretical Assessment
Determine the ideal catheter resistance given the hemodynamic data
retrieved in in-vivo experiments. The ideal catheter resistance was calculated
by assuming the outlet pressure received in-vivo would be the same for the actual
clinical setting of the implanted catheter. By use of Equation 3.1 again, a series of
manipulations were done to solve for the unknown variable, ideal catheter resistance.
ΔP = PIn − POut = QR,
POut = PIn −QR,
OPCatheter = IPCatheter −QR,
OPCatheterExperimental = OPCatheterActual ,
IPCatheterE −QERCatheterE = IPCatheterA −QARCatheterA ,
RCatheterA =
IPCatheterA − IPCatheterE +QERCatheterE
QA
(3.2)
Where RCatheterA is the theoretical ideal catheter resistance, IPCatheterA is typi-
cal arterial pressures at the proximal end of the catheter, IPCatheterE was the inlet
pressures detected at the proximal end of the experimental catheter of the grouped
in-vivo data, QE was the respective ﬂow rates of the grouped in-vivo data, RCatheterE
was the averaged experimental slopes of the ΔP and ﬂow curves of each animal, and
QA is typical arterial ﬂow rates the implanted catheter might experience.
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3.5 Statistical Analysis
All data was presented as mean ± standard error. Analysis of Covariance was used
to detect statistical diﬀerences between slope and y-intercept in linear ﬁtted results
using the statistical software GraphPad Prism 5 with p values p < .05, p < 0.01,
p < 0.001, and p < .0001, represented as *, **, ***, and ****, respectively. 2-sample
t-test was used to detect statistical diﬀerences between mean data (blood gas results)
in Minitab 17 with p values p < .05, p < 0.01, and p < 0.001 represented as *, **,
and ***, respectively.
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Fig. 3.7. This ﬁgure shows the diﬀerent muscles of interest for the
microsphere analysis of forward perfusion and retrograde perfusion
[43].
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4. RESULTS
4.1 Theoretical Basis
Determine how the catheter resistance relates to the physiological system.
By examining the experimental setup as a circuit, mathematical manipulations
were made to the setup to determine what variables of the system were known and
unknown. Through evaluation of the parameters displayed in Figure 3.1, the known
and unknown parameters are shown in Table 4.1.
The unknown variables, venous retro-vasculature and ideal catheter resistance,
were then determined through ex-vivo and in-vivo experiments.
4.2 Ex-vivo Experiments
Determine whether ﬂow reversals are possible.
In order to characterize the retro venous vasculature ex-vivo canine limbs were
investigated for practicality. First the venous valves were experimentally explored
for the best method of advancement to reach the distal limb. Figure 4.1 shows the
radiopaque hydrophillic guidewire advanced retrogradely through the venous system
all the way down into the dog’s foot under ﬂuoroscopy.
Determine if the retroperfusion hemodynamics is location dependent.
After the valves were experimentally determined to be passable, three distal ve-
nous locations were further explored. Figure 4.2 shows (A) the ’proximal’ location
(popliteal venous bifurcation), (B) the ’midway’ location (lateral saphenous vein bi-
furcation), and (C) the ’distal’ location (dorsum pedis vein) under ﬂuorscopy. Both
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Table 4.1.
Known and Unknown Parameters of Theoretical Circuit
Parameter Condition Clinical Location Clinical Speciﬁca-
tion
PressureInput Known Most Distal Satisfactory
Artery
Arterial Inputs
IPCatheter Known Proximal End of
Catheter Inside Artery
Mean Pressure of
∼100mmHg
Flow Known Proximal End of
Catheter Inside Artery
Flow Rate of
∼300ml/min
RCatheter Unknown Proximal End in Artery
and Distal End in Vein
Experimentally De-
termined
OPCatheter or
IPV asculature
Known Distal End of Catheter
Inside Vein
Target between 40-
60mmHg
RV asculature Unknown Retro Venous Vascula-
ture
Experimentally De-
termined
OPV asculature Known Distal End of Vascula-
ture
Assumed to be
0mmHg
proximal images show the extensive venous network at the popliteal bifurcation with
the right image displaying tortosity in the cranial tibial vein. The left midway image
shows an immediate shunt occurring in the medial saphenous vein and the right shows
the lateral saphenous vein with the same tortuous characteristic seen in the cranial
tibial vein. Both distal images display the various shunts when the ﬂow is far in the
foot.
After a venogram was made at each of the ex-vivo locations, the passive hemo-
dynamic characteristics were captured. An experimental setup that collected the
pressures at both end of the perfusing catheter and the ﬂow rate was put into place
after no backﬂow at the catheter was conﬁrmed. Graph A in Figure 4.3 shows the
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Fig. 4.1. This ﬁgure shows the guidewire down in the ex-vivo dog’s
foot thus surpassing all proximal venous valves.
raw data at each of the locations in which the data is fairly jumbled together in a
linear fashion. Graph B conﬁrms the linearity of the data once the data is cleaned
up into bins of 5ml/min (e.g. (0, 5]) with the average ﬂow rate and pressure shown
and their respective standard error.
To test whether the hemodynamics at each location was diﬀerent, Analysis of Co-
variance (ANCOVA) was performed to the test the statistical diﬀerence of the slopes
and y-intercepts. Graph A in Figure 4.4 shows each location’s linearized equation
and r-squared value. No slope was statistically diﬀerent, but the proximal and mid-
way’s y-intercept was signiﬁcantly diﬀerent from the distal location, p < 0.001 and
p < 0.01, respectively. Because the proximal and midway’s slope and y-intercept
were not statistically diﬀerent, their data was combined into one location, proximal.
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Fig. 4.2. This ﬁgure shows the ex-vivo locations under ﬂuoroscopy.
(A) is the proximal or popliteal venous bifurcation, (B) is the midway
or lateral saphenous vein bifurcation, and (C) is the distal or dorsum
pedis vein.
Graph B in Figure 4.4 shows the combined proximal data to the distal location, in
which the y-intercept is still statistically diﬀerent, p < 0.01.
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Fig. 4.3. This ﬁgure shows (A) the raw pressure ﬂow data at each of
the perfused sites and (B) the data put into bins of 5ml/min.
The hemodynamics at the popliteal vein bifurcation was explored in-vivo in an
active state.
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Fig. 4.4. This ﬁgure shows (A) the linearized data from each of the
locations and (B) the proximal and midway data combined for new
proximal data. ** represents statistical signiﬁcance of p < 0.01 and
*** of p < 0.001 vs each location’s y-intercept.
53
4.3 In-vivo Experiments
Determine the active hemodynamics at the retroperfusion site.
After an acute hindlimb injury was made, the active hemodynamic characteristics
were captured. An experimental setup that collected the pressures at boths end of
the perfusing catheter and the ﬂow rate was put into place after no backﬂow at the
catheter was conﬁrmed. Graph A in Figure 4.5 shows the raw data for each animal.
The data appears to be fairly linear and together. Graph B lumps the data into bins
of 5ml/min and is compared to the ex-vivo combined proximal data.
To further investigate the diﬀerences of the passive and active hemodynamics at
the popliteal vein bifurcation, the linearized portion of the data was ﬁt to a lin-
ear regression and their slopes and y-intercepts were compared using an ANCOVA
test. The slopes were not statistically diﬀerent but the y-intercepts were (p < 0.0001).
Determine the perfusion territory of venous reversed ﬂow compared to
arterial forward ﬂow.
To test where the reversed ﬂow went in-vivo, analysis of forward ﬂow at the
popliteal artery bifurcation (baseline) and reversed ﬂow at the popliteal vein bifur-
cation (retroperfusion) were compared using diﬀerent colored microspheres. Image A
in Figure 4.7 show an arteriogram at the popliteal artery bifurcation. Image B shows
an arteriogram after the initial contrast injection and reveals the contrast leaving the
leg through the lateral saphenous vein. A venogram at the popliteal vein bifurcation
is displayed in image C and D where image D shows both experimental catheters in
place.
Once the arteriogram and venogram were made to conﬁrm to the location, mi-
crospheres were injected. At the end of the experiment, muscle samples were taken
from various locations throughout the experimental distal limb. The muscle sam-
ples were digested and microspheres were ﬁltered from the digestion using a negative
pressure ﬁltration system. The ﬁltered micrspheres were then digested to allow their
respective ﬂuorescence to escape. The ﬂuorescence of each microsphere injection was
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Fig. 4.5. This ﬁgure shows the raw in-vivo pressure ﬂow data (A)
for each animal and (B) the data lumped into bins of 5ml/min and
compared to the ex-vivo combined proximal data at the popliteal vein
bifurcation.
detected, blue for baseline and yellow-green for retroperfusion. Graph A in Figure
4.8 shows the relative ﬂuorescence intensity per gram tissue of the forward perfusion
territory (baseline) and retrograde perfusion territory (retroperfusion). The relative
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Fig. 4.6. This ﬁgure shows the characteristics of the ex-vivo data
at the combined proximal location and in-vivo data at the popliteal
vein bifurcation. **** indicates p < 0.0001 vs each experimental y-
intercept.
levels of the retroperfused ﬂuorescence trends similarly to the respective location with
a slight increase in levels as the ﬂow reaches more distal muscle. Graph B shows the
ratio of retroperfused and baseline ﬂuorescence at each location, in which the dot-
ted line indicates the ratio of peak ﬂow rates in retroperfusion and forward ﬂow (0.44).
Determine the eﬀects of retroperfusion on an acute hindlimb ischemia
canine model.
To test whether the reverse ﬂow actually beneﬁted the ischemic tissue, blood
gas samples were taken throughout the experiment at pre-occlusion (n = 6), post-
occlusion 1 hour (n = 5), post-occlusion 2 hour (2-3 hours) (n = 4), and after
retroperfusion (n = 4). Graph A of Figure 4.9 shows the oxygen count of the outﬂow
blood (taken from Catheter A) decreasing during injury and trending back towards
baseline levels after retroperfusion in which the diﬀerences in inﬂow and outﬂow go
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Fig. 4.7. This ﬁgure shows (A) an arteriogram at the popliteal
artery bifurcation, (B) the injected contrast leaving through the lat-
eral saphenous vein, (C) a venogram at the popliteal vein bifurcation,
and (D) both experimental catheters in place.
from p < 0.001 at post-occlusion 2 hour to p < 0.05 after retroperfusion. Although
no statistical diﬀerence was shown between post-occlusion 2 hour and after retrop-
erfusion within outﬂow (p = 0.462), a loss of signiﬁcance was shown between inﬂow
and outﬂow, indicating the severity of the injury was decreased and thus a positive
eﬀect took place. The glucose levels in graph B show an increase in glucose uptake
(diﬀerence in inﬂow and outﬂow values) at post-occlusion 2 hour (p < 0.05) and after
retroperfusion no statistical diﬀerence between inﬂow and outﬂow blood samples was
detected (p = 0.350). Lactate levels (C) show a signiﬁcant climb at post-occlusion
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2 hour (p < 0.01) and fall back to no statistical diﬀerence value after retroperfusion
(p = 0.226). Graph D shows the pH of the outﬂow blood decrease at post-occlusion
2 hour (p < 0.001) and climb towards inﬂow values after retroperfusion (p < 0.05).
Table 4.2 displays the remaining noteworthy metabolic data from blood samples
through the in-vivo experiments. Partial pressures of carbon dioxide and oxygen, oxy-
gen saturation, and oxygen count all became statistically diﬀerent at post-occlusion
2 hour, p < 0.01, p < 0.001, p < 0.001, and p < 0.001, respectively. pO2 remained at
the same signiﬁcance after retroperfusion and SO2 dropped to p < 0.01. (Even though
medical oxygen put pO2 into unrealistic values, statistics were still run on the data.)
pCO2 and O2’s statistical signiﬁcance dropped to p < 0.05 after retroperfusion.
Table 4.2.
Blood Gas Results of Inﬂow and Outﬂow Blood Samples
Pre-Occlusion Post-Occlusion 1hr
Inﬂow Outﬂow Inﬂow Outﬂow
pCO2 (mmHg) 42.00±3.25 49.83±2.99 40.00±4.36 65.00±11.68
pO2 (mmHg) 501.17±11.63∗∗∗ 119.50±42.70 513.67±34.48∗∗∗ 109.80±68.18
SO2 (%) 101.5±0.07 84.37±.03 101.40±0.00 64.62±11.90
O2ct (mL/dL) 15.63±0.90 12.48±1.08 16.57±0.48 9.68±2.89
Post-Occlusion 2hr Retroperfusion
Inﬂow Outﬂow Inﬂow Outﬂow
pCO2 (mmHg) 44.00±5.51∗∗ 113.25±1.75 43.67±0.88∗ 103.00±12.00
pO2 (mmHg) 556.00±5.69∗∗∗ 31.50±3.48 486.00±10.07∗∗∗ 36.00±5.58
SO2 (%) 101.40±0.06∗∗∗ 24.40±3.66 101.30±0.06∗∗ 35.48±9.20
O2ct (mL/dL) 15.80±0.65∗∗∗ 4.23±0.70 17.30±2.60∗ 6.33±2.40
After the data was collected in-vivo, calculations towards an ideal perfusion catheter
could be made.
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4.4 Theoretical Assessment
Determine the ideal catheter resistance given the hemodynamic data
retrieved in in-vivo experiments.
From the hemodynamic data gathered in-vivo, the unknown variable, retro venous
vasculature resistance, was used to calculate the ideal catheter resistance. By using
Equation 3.2 the pressure and ﬂow of the experimental data dependent on the venous
vasculature was used to calculate the ideal catheter resistance. Table 4.3 displays
the ideal catheter resistance given an inlet pressure between 80 and 120 mmHg, a
catheter output pressure equal to in-vivo data, and inlet ﬂow rates between 100 and
300 ml/min. The target catheter output pressures are boxed. The table shows that
when a pressure of 100 mmHg and ﬂow rate of 200 ml/min enter the catheter, a
resistance of 0.585 mmHg/ml/min is required for a retroperfusion pressure of around
50 mmHg.
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Table 4.3.
Ideal Catheter Resistance Given an Inlet Pressure, a Catheter Output
Pressure Equal to In-vivo Data, and Inlet Flow Rates
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Fig. 4.8. This ﬁgure shows (A) the relative ﬂuorescence intensity per
gram tissue of the forward perfusion territory (baseline) and retro-
grade perfusion territory (retroperfusion) at various distal limb mus-
cles and (B) the ratio of perfusion ﬂuorescence. The dotted line indi-
cates the ratio of peak ﬂow rates in retroperfusion and forward ﬂow
(0.44).
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Fig. 4.9. This ﬁgure shows the metabolic results of blood samples
from inﬂow and outﬂow blood taken at pre-occlusion, post-occlusion
1hr, post-occlusion 2hr, and after retroperfusion. (A) is the oxygen
content, (B) glucose, (C) lactate, and (D) pH. *,**,** indicate p < .05,
p < 0.01, and p < 0.001, respectively, for inﬂow and outﬂow values
above the speciﬁed event.
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5. DISCUSSION
Globally, over 200 million people suﬀer from peripheral arterial disease [44] and ap-
proximately 1 million amputations are performed every year [45]. In the United States
these numbers reach 8 to 12 million [12] and 185,000 [46], respectively. Over half of
all amputations performed are due to vascular disease [45, 46], particularly critical
limb ischemia, the most severe form of PAD, of which 5-10% of typical claudicants
will acquire within 5 years of diagnosis [10]. Within the ﬁrst year of of CLI diagnosis,
30% require a major amputation and 25% will die [10, 47]. Thus, the need for limb
salvage is clearly a concern for all stages of peripheral arterial disease.
Revascularization techniques for these amputee-fated patients have been explored
sporadically over the last century and mainly occupied by reversed ﬂow techniques
[19, 20, 24, 25, 29, 30, 33–37]. Initially, ﬂow reversal was explored by connecting an
artery to its neighboring vein in-situ in an attempt to restore ﬂow in the ischemic
areas [19,24,26]. Typical shortcomings were from valve competency prohibiting distal
ﬂows [19,24,25] to uncontrollable edema [25] and some ended in heart failure due to
the high cardiac output as a result of venous-venous shunting [24, 27, 38]. Recent
clinical studies [33–36] excise an accessory vein, strip it of its native valve, attach to
it a patent artery, and attach to a major foot vein to ensure distal ﬂow. Although
this approach is much more invasive and timely, the results have shown high salvage
rates.
It was our belief that the concerns of both retroperfusion techniques could be
overcome in a minimally invasive/catheter based approach in which the catheter
itself provides a engineered speciﬁed resistance that avoids edema and the perfusion
location allows for valves to be passable and ﬂow to reach distally. This approach
merges the advantages of both retroperfusion techniques without the repercussions of
each of the techniques.
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Our study was broken up into a series of phases: a theoretical assessment, an
ex-vivo proof of concept, an in-vivo validation of the ex-vivo results and gathering of
data, and ﬁnal calculations of an ideal catheter. The theoretical assessment broke up
the study in an engineering approach, which revealed what unknown parameters were
needed for an ideal catheter. The ex-vivo experiments where done to show where and
what ﬂows are possible in retroperfusion, to further indicate what perfusion location
to explore in in-vivo, and what hemodynamics we might expect at that location. The
in-vivo experiments addressed the hemodynamics of the perfusion location under
injury, where the reversal ﬂow actually went compared to forward arterial blood ﬂow,
and whether the retroperfusion showed any positive signs of reversing the injury. The
hemodynamic data gathered in-vivo was then added to the theoretical assessment to
calculate the ideal catheter resistance needed to obtain a perfusion pressure that will
not result in edema.
5.1 Determine how the Catheter Resistance Relates to the
Physiological System.
The theoretical basis of the study gave direction for what experiments needed to
be done to support the overall hypothesis.
By examining the clinical setting of the catheter in series with the venous vascula-
ture, we could easily solve for the variables of the system analytically. Though some
studies have put great detail into representing the vascular system as an electrical
circuit and parameter characterizations [48–52], our model was only intended to be
used as a tool to pull out approximate relationships to guide the study into further
experiments and not as an absolute characterization of the system.
Table 4.1 shows each parameter, whether it is known, where it is located, and
the speciﬁcations of each. The PressureInput would come from the most distal satis-
factory artery and supply the catheter with the arterial inputs. The input pressures
from the artery (IPCatheter) were expected to be in range of femoral artery supine
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and standing values, between 90-150 mmHg [1]. For femoral artery ﬂow rates, it has
been shown in healthy humans to range from 300-400 ml/min [53–56] when resting in
supine position. Resting values were shown to be the nearly the same for intermittent
claudication and critical limb ischemia 436 and 307 ml/min, respectively [56], and 401
ml/min for all PAD patients [55]). Output pressure of the catheter (OPCatheter) in the
venous system was targeted between 40-60 mmHg, because it has been shown that
retrograde venous pressures greater than 60 mmHg damage venules [57]. Our lab has
previously suggested to target a pressure of 50 mmHg, the mean of typical arterial
and venous pressures, thus 40-60 mmHg was the targeted output pressures [22, 58].
The last known parameter, vasculature output pressure (OPV asculature) was assumed
to be 0 mmHg for simplicity. The vasculature output pressure was considered to be
located where the pressure is equal to 0 mmHg rather than the venous end of the
capillary bed. This assumption allows for the vasculature to represent a much more
complex network.
From here, the only parameters left were the unknown variables: catheter resis-
tance (RCatheter) and venous retro-vasculature resistance (RV asculature). In order to
determine the ideal catheter resistance needed to obtain the target output pressures,
the venous retro-vasculature resistance was needed because the pressure drop across
the catheter is relative to the resistance of the vasculature. In other words, if the
resistance of catheter is much greater than the resistance of the vasculature, then the
catheter will take up nearly all the pressure leaving little output pressure and if vice
versa the catheter will maintain nearly all the pressure from the inlet thus resulting
in very high pressures in the venous system. Neither case is ideal because, according
to Zweifach 15 to 40 mmHg of pressure is needed at the capillary level for ﬂow and
nutrient exchange, but pressures greater than 40 mmHg results in sudden edema in
the capillary bed [8].
The venous retro-vasculature resistance was determined experimentally as the
slope of a pressure ﬂow curve. Once a value was given to this variable the ideal
catheter resistance resulting in the target output pressures was solved for.
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5.2 Determine the Resistance of the Venous Retro-Vasculature
Most Suitable for Eﬀective Retroperfusion.
5.2.1 Determine Whether Flow Reversals are Possible.
Because previous retroperfusion eﬀorts had issues rendering the valves incompe-
tent, exploration of if and where ﬂow reversal were even possible was required. Ex-vivo
canine hindlimbs were the initial experimenting platform due to their abundant sup-
ply, similiar peripheral vascular system to humans, and their vascular system being
easily attainable [25, 29].
An early attempt at retroperfusion looked as if ﬂow reversal would not be possible.
Figure 5.1 shows the massive change in pressure with little changes in ﬂow when ﬂow
was fed into the femoral vein retrogradely as opposed to a near one to one relationship
from forward ﬂow in the femoral artery. This quick experiment was a quick reminder
from literature that very proximal venous valves are extremely diﬃcult to render
incompetent to ﬂow [19].
A brief feasibility check was performed in-vivo to determine if the mighty proximal
valves were passable at all. Figure 5.2 shows the valves being passed with a guidewire
at the iliac level to midway of lateral hindlimb. The contract injections show imme-
diate back ﬂow towards the heart in images A-C. It was concluded that the venous
valves were passable retrogradely, but a hydrophilic guidewire and forward ﬂow were
considered necessary to reach distal veins.
5.2.2 Determine if the Retroperfusion Hemodynamics is Location Dependent.
Once the femoral level valves became easy to routinely pass we then began to
gather hemodynamic data throughout the limb. A ’proximal’ location (popliteal vein
bifurcation) was explored, a ’midway’ location (lateral saphenous vein bifurcation),
and a ’distal’ location (vneous dorsum pedis). Because the hemodynamics were as-
sumed to be location dependent, these three locations were investigated.
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Fig. 5.1. This ﬁgure shows an early attempt at retroperfusion in the
femoral vein compared to forward perfusion at the femoral artery.
The qualitative results shown in Figure 4.2 display the shunting eﬀects at the
midway and distal location. Figure 5.3 clearly shows the major escape routes the
ﬂow can take when the ﬂow is supplied in the foot. The quantitative results shown in
Figures 4.3 and 4.4 indicate no statistical diﬀerence between the slopes but the distal
location does have a signiﬁcantly diﬀerent y-intercept. The slope was interpreted
as the resistance of the system (venous vasculature) due to simplicity of the system
design, in which others have considered the pressure-ﬂow relationship as resistance
[49,50,59] or vascular impedance [60] for arterial antegrade ﬂow. The y-intercept was
interpreted as the equilibrium pressure when no ﬂow is present, similar to the mean
circulatory ﬁlling pressure, or the residing pressure in the vasculature once the heart
stops beating [1,52]. Because the y-intercept is signiﬁcantly less for the distal location,
we assume this is due to less compliant veins being ﬁlled at the distal location. Thus
less collapsed vasculature to ﬁll would result in a lower y-intercept [51,59]. Antegrade
arterial pressure-ﬂow studies have looked into this ’zero-ﬂow pressure’ as the eﬀective
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Fig. 5.2. This ﬁgure shows the distal venous system of a canine
hindlimb being accessed in-vivo. (A) shows the iliac/femoral region,
(B) the popliteal region, (C) the distal femoral caudal region, (D) the
lateral saphenous region, and (E) the cranial lateral saphenous region.
downstream pressure to arterial ﬂow that onsets vascular waterfall [51,52,59,61], the
pressure height that must be reached before any subsequent ﬂow is met or also known
as the critical closing pressure. In our study is it assumed that the antegrade critical
closing pressure is similar to our retrograde y-intercept of mean circulatory ﬁlling
pressure.
For simplicity, because the proximal and midway locations were not statistically
diﬀerent their data was combined to represent a new combined proximal data set.
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Fig. 5.3. This ﬁgure shows the distal shunting eﬀects of ﬂow.
5.2.3 Determine What Location Seems Most Promising for
Eﬀective Retroperfusion.
The hemodynamics did not prove to be as location dependent as we originally
thought. Between the two distinct locations of the popliteal vein bifurcation and
dorsum pedis, the proximal location indicated favorable qualitative characteristics as
an in-vivo perfusion site since the distal location clearly showed immediate venous-
venous shunting. Clinically, if too much shunting occurs it is assumed that little
to no blood will reach the microvasculature to salvage the ischemic limb [27] and
the body will compensate by increasing cardiac output in which heart failure can
occur [24,27,38]. To investigate the proximal location more thoroughly, the pressure
wire was kept distal past the perfusion location to detect distal pressures. Figure
5.4 shows the pressures reached at the midway, distal, and very distal locations were
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relative to the pressure at the tip of the catheter at the popliteal vein bifurcation.
Because pressures were being reasonably maintained past the tip of the catheter it
was assumed that a reasonable amount of the ﬂow was reaching the same locations.
With these encouraging results, it was hypothesized that the popliteal vein bifurcation
would make a successful retroperfusion location in-vivo since ﬂows were indicated past
the site of perfusion with no signs of venous-venous shunting. A possible explanation
for no signs of venous-venous shunting could be due valve direction that plays a part
in ﬂow movement, such that perforating veins move ﬂow from superﬁcial to deep and
prevent deep reﬂux into the superﬁcial system [3,27,62]. By the valves in perforating
veins preventing deep to superﬁcial venous ﬂow, one could assume that at the popliteal
bifurcation, being as it is part of the deep system, perforating veins would act in favor
of continual deep reversed ﬂow.
Fig. 5.4. This ﬁgure shows evidence of distal pressures when the
retroperfusion site is at the popliteal vein bifurcation.
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5.3 Determine the Resistance of the Venous Retro-Vasculature and Characteristics
of Retroperfusion In vivo.
A hindlimb ischemia model was performed prior to in-vivo retroperfusion. The
injury model displayed in Figure 3.4 needed to be aggressive since all the experiments
were done acutely. Threshold for muscle ischemia recovery has been claimed to be
between 2-6 hours [63–65] and several studies have shown extreme metabolic eﬀects
after 3 hours of occlusion [66], thus our occlusion time was between 1-3 hours with
ultrasound and direct angiography veriﬁcation [67,68].
It has also been conﬁrmed that multiple occlusions closer to the aorta produce
more profound ischemic eﬀects than single distal ligations (e.g. femoral level) [68,69]
in which Rosenthal showed collateral compensation within the ﬁrst hour of femoral
artery occlusion in canines [70]. Despite clinical evidence of severe ischemia, even
ligatures of rat common iliac, femoral, and branching on a single limb have shown
maintenance of blood ﬂow in the ischemic limb [71]. In addition, bilateral ligations
have also shown to create a more severe ischemic limb in a rat model [68]. It is typical
for rat and canine models to need more aggressive limb injuries due to their abundant
collateral network compared to a rabbit or pig model whom show a human-like ab-
sence of limb collateral network [68]. An adverse eﬀect of placing the retroperfusion
catheter sheath in the distal vena cava caused arterial and venous occlusions which
was thought to attribute to the severity of the ischemia [67]. Ligations in the non-
experimented leg and terminal aorta were made to prevent any possible immediate
collaterals to the experimental leg [68, 72, 73] and thus no control leg was made in
the experiments. All major native collaterals were intended to be avoided to ensure
all eﬀects post-retroperfusion could be conﬁrmed by retroperfusion and not by collat-
eral compensation. This avoidance was considered important since the patients being
treated are not likely to have major collateral compensation in their poorly perfused
distal limb. To capture noncollateral eﬀects, one group looking at ischemic metabolic
levels went as far as to take measurements immediately after killing the animal to
avoid confusion of collateral eﬀects on muscles ischemia [74], a solution that would not
71
make sense here for in-vivo data collection. The acute experiments were performed
on mongrel dogs with 10 weeks of venous hypertension. The state of the dogs were
considered ideal since their venous system was preconditioned to higher pressures
and wall thickening had already occurred [20,75]. This is the vascular state that the
veins clinically will become prior to full implantation by allowing distal catheter ﬂow
to travel antegrade or retrograde for several weeks before closure at the tip for only
distal ﬂows.
5.3.1 Determine the Active Hemodynamics at the Retroperfusion Site.
Because retroperfusion would only take place in an ischemic limb and ﬂow will
only occur when a pressure diﬀerence exists, an ischemia model was needed to gather
realistic retroperfusion data.
The popliteal vein bifurcation was chosen to be the retroperfusion site because of
the ex-vivo results, the most successful in-situ ﬂow reversal as previously been the
popliteal vein bifurcation [29,30], and because it was previously shown that the venous
valves did not aﬀect retro-ﬁlling at this location [76]. After the injury had set for 1-3
hours, retroperfusion was performed for approximately one hour. Figure 4.5 shows the
raw data from each animal and then compared to the ex-vivo results. The signiﬁcant
diﬀerence in the y-intercepts are displayed in Figure 4.6. A similar diﬀerence has
been shown between instantaneous and steady-state pressure-ﬂow relations at femoral
artery level [49,59,61] in which the steady state allows for arteriole compensation as
shown by the curvature of the response and instantaneous captures the true physical
resistance typically shown as linear [49, 59, 61, 77, 78]. However, here we collected
data points every 30-45 seconds for ex-vivo and every 1-3 minutes in-vivo, making
our pressure-ﬂow data steady state. The slight curvature to the in-vivo data could
be explained by the vascular response to the retro ﬂows and pressures but for ex-
vivo no vascular response could be made in the dead tissue hence the non-curvature
relationship.
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The y-intercept diﬀerence is again assumed to be characterized by the ﬁlling pres-
sure. In the ex-vivo experiments the veins were collapsed causing more pressure
needed to get any resulting ﬂow, but in in-vivo experiments little pressure is needed to
distend the veins and result in ﬂow of which our value relates to literature MCFP [1].
Although the y-intercepts are signiﬁcantly diﬀerent, the slopes indicate that venous
retro-vasculature resistance are similar from the passive to active state. Aside from
the curvature of in-vivo data, this observation could suggest that, acutely, the venous
retro-vasculature resistance has no active properties aﬀecting the overall resistance of
the periphery.
The hemodynamic data of the retro venous system collected in-vivo provided
the missing information needed to calculate the catheter resistance that limits the
perfusion pressure to a healthy range.
5.3.2 Determine the Perfusion Territory of Venous Reversed Flow Compared
to Arterial Forward Flow.
Fluorescent microspheres were injected to gather information as to where the retro
ﬂow actually went during retroperfusion. If no ﬂow was shown to make it to ischemic
muscles throughout the limb, support of the actual device would be limited. The
perfusion territory of baseline of forward arterial ﬂow was compared to the perfusion
territory of retroperfusion of reverse venous ﬂow. Two very diﬀerent ﬂuorescent mi-
crospheres were injected for each case to ensure no spillover eﬀect [71] and the overall
methods of injection and analysis followed that of the Fluorescent Microsphere Re-
source Center [41, 42].
The relative levels of the retroperfused ﬂuorescence in Figure 4.8 trends similar to
the baseline ﬂuorescence at a respective location with a slight increase in levels as the
ﬂow reaches more distal muscle (further down the x-axis). The ratio of retroperfused
and baseline ﬂuorescence at each location hovers around the dotted line which indi-
cates the ratio of peak ﬂow rates in retroperfusion (37 ml/min) and forward venous
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ﬂow (85 ml/min) of 0.44. We assume if higher ﬂow rates were reached, the levels
of retroperfusion would increase as well. It has been suggested that retro-ﬂow rates
of 60 ml/min are needed to salvage the limb [79], though here our max rates only
reached near 40 ml/min, a note that will weigh into the chronic validation model and
the targeted ﬂows.
The slight upward increase in ﬂuorescent levels in the more distal muscle is thought
to be due to the perfusion territory becoming more localized as the ﬂow makes its
way to the distal limb, in which this localization is considered necessary for ﬂow in
the foot [20].
5.3.3 Determine the Eﬀects of Retroperfusion on an Acute Hindlimb Ischemia
Canine Model.
To evaluate if retroperfusion at the chosen perfusion site had any metabolic eﬀect
on the ischemic hindlimb, blood samples were retrieved throughout the experiment
before and after occlusion and after retroperfusion. The blood gas results shown in
Figure 4.9 indicate onset of anaerobic glycolysis at post-occlusion 2 hour due to the
signiﬁcant decrease in oxygen count, signiﬁcant increase in glucose uptake and lactate
production, and signiﬁcant drop in pH [74]. Younger explained that high lactate levels
could be misleading if the site of retrieval is very close to ischemia induced site in which
extreme local eﬀects would outway the eﬀects of musculoskeletal hypoperfusion [80].
This was not a concern of ours since the occlusion site was the aortic bifurcation
and retrieval was at the popliteal level thus the lactate levels was assumed to do to
musculoskeletal hypoperfusion.
Our baseline lactate levels, shown is Figure 4.9, were similar to another animal
study [81]. Peak lactate levels were similar to previous animal studies when skeletal
muscle ischemia was induced by 1 and 6 hours of arterial occlusion [82, 83], respec-
tively, and immediate death [74]. Speciﬁcally, Kabaroudis showed no signiﬁcant dif-
ference in canine popliteal venous lactate levels between 1, 6, and 12 hours of femoral
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artery occlusion and very similar glucose levels for baseline and peak injury (their
12 hour, our 2 hour) [82]. The diﬀerence in occlusion times to metabolic severity is
thought to be caused by the diﬀerence in the occlusion methods, in which ours was
at the aortic bifurcation.
Due to the lack of oxygen, anaerobic glycolysis was the only long term energy
mechanism that could take place [74,84]. Glucose levels, shown is Figure 4.9, dropped
in outﬂow due to uptake in glycolysis and lactate levels increased due to fermentation
in which lactic acid is produced in order to continue ATP production in glycolysis.
The lactic acid buildup then decreased pH levels in the outﬂow. After approximately
one hour of retroperfusion, the signs of anaerobic glycolysis decreased, though not
signiﬁcantly. However, Figure 4.9 shows the oxygen count and pH levels remained
signiﬁcantly diﬀerent from inﬂow (p < 0.05 v. p < 0.001) when glucose and lac-
tate levels were no longer signiﬁcantly diﬀerent from the inﬂow levels, suggesting a
signiﬁcant trend back to baseline levels.
The oxygen levels in Table 4.2 shows the metabolic response to partial pressures of
carbon dioxide and oxygen, oxygen saturation, and oxygen count. Here, even though
the outﬂow levels of each trended back towards baseline values, although their levels
remained statistically diﬀerent to inﬂow.
Evaluation of retroperfusion post-injury was critical to prove the potential of the
perfusion site. By showing the signs of anaerobic glycolysis were somewhat reversed
post-retroperfusion, we are hopeful that this observation will continue and strengthen
in a chronic peripheral arterial disease model.
5.4 Determine the Ideal Catheter Resistance Given the Hemodynamic
Data Retrieved in In-vivo Experiments.
The in-vivo experimental pressure-ﬂow data provided us with the necessary data
to calculate the ideal catheter resistance needed chronically and clinically. The ﬂows
rates experienced in-vivo were much lower than those expected chronically and clin-
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ically from the arterial input when the catheter will have native inﬂows from the
femoral artery or higher (our max reached retro ﬂows of 40 ml/min vs. canine
femoral artery ﬂows of 60-140 ml/min [25, 28, 85, 86] vs. human femoral artery ﬂows
of 300-450 ml/min for normal and PAD patients [53–56]). Also, inﬂow pressures are
expected to be diﬀerent as well (canine femoral artery pressure of 130 mmHg [70,85]
vs. human femoral artery pressure of 100 mmHg [1]). Because of this, a few extra
manipulations were needed to calculate the catheter resistance, shown in Section 3.4.
A table of ideal catheter resistances given an input/arterial pressure, target perfu-
sion pressures, and arterial ﬂow rates was made for reference for the optimal catheter
design of which would be used in clinical setting (Table 4.3). The input arterial
pressures and ﬂow rates were given a range because not all the pressure and ﬂow is
planned to be diverted into the retroperfusion catheter thus a range was examined.
The middle pressures were boxed because they are near the target output pressures.
The table is intended to be used as a tool for a ﬁnal catheter design. For example,
if the design engineer knows the ﬂow rate will be in a ﬁner ﬁxed range, then the
catheter resistances can be conﬁned to a more precise value and thus the likeliness of
the device success can be theoretically more supported.
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6. CONCLUSIONS
Being able to indicate very distal reversed ﬂows and show signs of acute ischemia
reversal by retroperfusion at a speciﬁc perfusion location validates further eﬀorts of
this proof of concept. In order to be conﬁdent in this method of perfusion, a chronic
study is critical to prove its potential. In the chronic model a shunting device of ideal
resistance calculated in this study will take the place of the extracorpeal circuit and
will be directly implanted from artery to vein. The device itself will account for the
optimal pressure drop and retrogradely perfuse at nearly a constant pressure. It is
expected that the retroperfusion eﬀects will hold true past any acute responses and
adequate collateralization will form to reroute the blood to and from the ischemic
sites. If the chronic results are promising, severe peripheral arterial disease patients
will ﬁnally have a treatment option in which they can keep their limbs.
6.1 Limitations and Future Work
The major limitations of the study mainly fall on how all the in-vivo eﬀects came
from acute experiments rather than chronic experiments. Clearly, the next step of
the study is to take the ﬁndings found here throughout the study and apply them to
a chronic animal model.
Catheter resistance, and location and success of the retroperfusion device was
demonstrated here in the deep system at the popliteal vein bifurcation. Possibility
of reversed ﬂow here, how to reach this location retrogradely, and why this location
was most promising was shown in this study, as supported by no signs of shunting,
previous chronic success, detection of distal ﬂows in ischemic muscles, and acute
indication of reversed injury through reversed ﬂow. Although many ﬁndings were
made, a few limitations of the study include the dynamics of blood pressure and
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ﬂow and its overall eﬀect on the catheter, further validation of retroperfusion success,
time to develop injury, time to observe retroperfusion eﬀects, and ischemic animal
model not being speciﬁc for critical limb ischemia. In addition, more time could have
been spent in the early stages of the study, further supporting the retroperfusion
location, however the ex-vivo studies were done purely to guide the more meaningful
in-vivo experiments and work out experimental hurdles rather than spending time
characterizing ‘dead tissue’.
Dynamics of the System. It is important to consider the hemodynamic eﬀects on
standing compared to resting supine levels, in which all previously cited literature
and parameter values are from resting supine. Even though all the pressure and
ﬂow collected throughout the study all came from pulsatile data (catheter outﬂows
pressures had a mean peak to peak value of 14 mmHg, a pulsatility between artery
and vein, Figure 1.3 [1]), only the mean values were plotted and referred to of which
came from resting supine position. For femoral artery ﬂow rates, it has been shown in
healthy humans to range from 300-400 ml/min [53–55] when resting in supine position
and to drop to ∼200 ml/min when standing [56]. Resting values have been shown
to be the nearly the same for intermittent claudication and critical limb ischemia,
436 and 307 ml/min, respectively, and 401 ml/min for all PAD patients [55], but
when standing intermittent claudicants drop to 220 ml/min near healthy standing
range whereas CLI patients increase to nearly 500 ml/min. Femoral level pressures in
healthy humans increase to 150 and 60mmHg for artery and vein from approximately
90 and 5 mmHg, respectively [1], although these values are reduced to near resting
supine after about ten steps [3]. Eﬀects of catheter resistance should be examined
at these ‘active’ cases to determine whether edema can be avoided during standing
and/or walking with the device implanted or if the implant will only result in limb
salvage at rest. By using part of the venous system as a perfusion route to the distal
limb this takes away part of the venous systems’s ability to control for pressure, thus
it is assumed that pressure will not be as easily regulated. It is also assumed that
blood ﬂow will be diﬃcult to regulate prior to venous arterialization and angiogenesis
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since arterioles are the main regulators of ﬂow and won’t have major contribution
until either of the two events occur. However, limb salvage at rest in itself can
avoid amputation but avoidance of complications and continued limb salvage during
standing/walking could make the device much more valuable and/or explain successes
or failures in previous ﬂow reversal attempts.
Further Validation of Acute In-Vivo Experiments. To add a layer of validation of
retroperfusion in the acute in-vivo studies, more ischemia and ﬂow analysis could have
been done. Muscle biopsies for ischemia detection would have conﬁrmed the level of
injury throughout the skeletal muscles in the study and again after retroperfusion to
conﬁrm if metabolic levels were reversed and to support the outﬂow blood samples
taken at the popliteal level. Biopsies were taken throughout the study but were not
analyzed for this thesis. Planned analysis methods include NADH-tetrazolium [83]
and hematoxylin and eosin staining [87] for ischemia detection and edema detection,
respectively. Surface pO2 (or transcutaneous pO2, TcpO2) levels would have also
added a layer of acute retroperfusion success as others have shown likelihood of wound
healing is promising when TcpO2 is >40 mmHg, and unlikely when <20 mm Hg
[16]. This was attempted during the study but results were unreliable due to lack of
equipment sensitivity.
Future Endpoints. Analysis methods for chronic study should include a combi-
nation of qualitative functional scoring similar to Tarlov scale [67], metabolic de-
tection of outﬂow lactate and/or glucose [68, 81, 82], pulse detection in toes [24, 38],
ﬂow/perfusion detection (using laser doppler perfusin imaging and/or angiography
[67–69]), oxygen detection (using transcutaneous oximetry), pressure detection (using
ABI index and/or TBI index) throughout the study [16] and ﬂow/perfusion detection
of collaterals and capillaries (using microspheres [71] and/or immunohistochemical
stainings [67–69]) collected at the end of the study.
Animal Model Criticism. Like nearly all PAD animal models, our model was
not speciﬁc for the targeted disease [62, 68, 72, 88]. However, for our acute study,
the aggressiveness of the injury showed metabolic ischemic eﬀects within the critical
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ischemia time of 2-6 hours [63–65] relative to literature values. However, no reversed
ﬂow studies examined the ischemic metabolic levels prior to experimental reversed
ﬂow, either nothing [25, 29] or only pressure ratios, pulse detection, oxygen tension,
and surface pH [24] were examined. Our occlusion time allowed us to get initial
insight of the response of controlled reversed ﬂow with ensured ischemia. Other
studies that produced irreversible injury applied ﬂow reversal immediately [25,29] or
only allowed 30 minutes of stabilization [24] due to the severity of the injury and then
had reversed ﬂow for 30 minutes [24] for detection of acute eﬀects or others waited
10-14 days for chronic eﬀects [25,29]. Some studies performed no type of injury before
observing reversed ﬂow eﬀects [28,86,89] or performed minute occlusions for a couple
of minutes and then observed results [85]. Ours looked at the acute ischemic response
and retroperfusion response. Compared to other reverse ﬂow studies, we allowed
longer time for the injury to set before observing retroperfusion eﬀects, arguably
making our results more relevant.
Chronic Animal Model of PAD. The animal model for chronic experiments should
be taken into great consideration. A model that avoids native collateral ﬂow is critical
in order to validate the retroperfusion catheter. Because most studies look at ischemia
models to study collateral formation our model must avoid this. Rosenthal showed
the sensitivity of collateral formation when systemic pressure was halved, even when
no occlusion was set in place, a compensation that severe PAD patients lack [70].
Because severe PAD patients have issues to ﬂow compensation a model that supports
this would be futile in validation of the study. It is reasonable to have multiple levels
of validating chronic studies with alterations in the animal model more similiar to
the disease itself. A model that shows irreversible ischemia could be a ﬁrst step, like
the animal model developed by Graham [29, 30]. A more validating animal model
that would avoid using only simple occlusions and provide some type of endothelial
dysfunction like that of patients with critical limb ischemia through addition of hy-
perlipidemia or diabetes model [62, 68, 88] would be an more ideal animal model to
test the device in prior to clinical trials.
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